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RESUMEN 
Tras el reconocimiento del antígeno, los linfocitos B pueden iniciar la reacción de centro 
germinal (GC), en la cual diversifican sus genes de inmunoglobulinas, mediante las reacciones de 
hipermutación somática (SHM) y cambio de isotipo (CSR), dando lugar a células plasmáticas o B 
memoria. La transición a través de los diferentes estadios de esta reacción implica la expresión 
coordinada de redes de genes que permiten una correcta diversificación de los linfocitos B. A 
nivel molecular, las reacciones de SHM y CSR se desencadenan por la desaminación de citosinas 
en los genes de las inmunoglobulinas, mediada por AID. La actividad de AID en linfocitos B no 
está restringida a los genes de las inmunoglobulinas, pudiendo introducir mutaciones en otros 
genes y mediar translocaciones cromosómicas con potencial linfomagénico. Además, AID puede 
expresarse en epitelio en respuesta a inflamación, sugiriendo un posible papel de AID en el 
desarrollo de carcinoma. 
En la primera  parte de este trabajo, se ha abordado el papel del remodelador de cromatina 
CTCF en la reacción de GC. Los datos obtenidos demuestran que CTCF es absolutamente 
necesario para el GC, pudiendo ser esta necesidad sobrepasada in vitro mediante la estimulación 
con citoquinas. El análisis transcripcional reveló que la deficiencia de CTCF desregula numerosos 
genes implicados en la reacción de GC así como en células plasmáticas, incluyendo Blimp-1. De 
hecho, el fenotipo asociado a la deficiencia de CTCF puede ser parcialmente revertido 
restableciendo los niveles de Blimp-1. En conjunto, los datos presentados sugieren que CTCF es 
un regulador maestro del GC, actuando en el mantenimiento del programa de GC y previniendo 
la diferenciación a célula plasmática.  
En la segunda parte del trabajo, se ha testado el papel de AID en el desarrollo de carcinoma 
epitelial, mediante la generación de modelos murinos de sobre-expresión de AID en colon y 
páncreas. Mediante esta aproximación se vio que AID por sí misma no es capaz de promover la 
aparición de carcinomas, a pesar de introducir mutaciones y desencadenar una respuesta 
genotóxica. En cambio, AID promueve la expresión de ligandos NKG2D en páncreas, el 
reclutamiento de linfocitos CD8+ y la inducción de muerte en el epitelio. Nuestros resultados 
indican que el potencial oncogénico de AID en células epiteliales puede ser neutralizado por un 
mecanismo protector de inmunovigilancia.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ABSTRACT 
 
After the recognition of the antigen B lymphocytes can engage into the Germinal Center (GC) 
reaction, where they diversify their immunoglobulin (Ig) genes by somatic hypermutation (SHM), 
class switch recombination (CSR) and from where terminally differentiated plasma or memory B 
cells emerge. Transition through these different stages involves coordinated expression of gene 
networks that define transcription programs required for a proper B cell diversification.  At 
molecular level, SHM and CSR are triggered by AID-mediated deamination of cytosines in Ig 
genes and can promote mutations and pro-lymphomagenic translocations. Importantly, AID 
activity in B cells is not restricted to Ig loci and can be expressed in response to inflammatory 
cues in epithelial cells, raising the possibility that AID mutagenic activity might drive carcinoma 
development.  
In the first part of the work, the role of the chromatin remodeling factor CTCF during the GC 
reaction was addressed, as potential transcriptional regulator during this process. We found that 
CTCF is absolutely required for the GC reaction. Surprisingly, cytokine stimulation can rescue the 
need for CTCF for B cell activation in vitro. Transcriptome analysis has revealed that CTCF 
deficiency deregulates numerous genes involved in the GC reaction and in plasma cell, including 
Blimp-1. Indeed, we have found that CTCF deficiency is partially rescued by re-establishing 
Blimp-1 levels. Together, our data suggest that CTCF is a master transcriptional regulator of the 
GC reaction by maintaining the GC program and preventing plasma cell differentiation. 
In the second part, the role of AID in carcinoma development was tested by generating 
conditional knock-in mouse models for AID overexpression in colon and pancreas epithelium. 
AID overexpression alone was not sufficient to promote epithelial cell neoplasia in these tissues, 
in spite of displaying mutagenic and genotoxic activity. Instead, we found that heterologous AID 
expression in pancreas promotes the expression of NKG2D ligands, the recruitment of CD8+ T 
cells and the induction of epithelial cell death. Our results indicate that AID oncogenic potential 
in epithelial cells can be neutralized by immunosurveillance protective mechanisms. 
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Natural killer cell 
Natural killer group 2 member D 
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Quantitative real time polymerase chain reaction 
Retinoic acid early inducible 
Somatic Hypermutation 
Sheep red blood cells 
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T cell receptor 
T follicular helper cells 
T helper cell 
Uracyl DNA glycosilase 
Western Blot 
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1. Immune system and adaptive immunity 
The immune system is a very sophisticated mechanism to protect organisms against 
foreign agents. A key feature of the immune response is the identification of factors as 
potentially pathogenic. All animals possess a primitive system of defense called innate 
immunity, which is based in the recognition of molecular patterns commonly present in 
pathogenic agents. The innate response is a first rapid, efficient and nonspecific barrier 
against pathogens, and allows their efficient elimination in an unspecific way. In addition, it 
plays an important role in the activation of the adaptive immune response. This adaptive 
response is a most sophisticated system of defense that has evolved in vertebrates.  The 
hallmark of the adaptive immune response is the diversity of their antigen receptors that 
allow a high specific recognition of pathogens and the development of immune memory, 
what makes possible a faster and more efficient elimination of the pathogen in future 
infections.  
T and B lymphocytes, or cells, are the effector cells of the adaptive immunity. T cells are 
involved in the elimination of intra-cellular pathogens and in the activation of a number of 
immune cells. On the other hand, B cells are specialized in the development of humoral 
immune responses against extra-cellular pathogens. The function of both T and B cells relies 
on the expression of extremely diverse receptors for antigen T cell receptor (TCR) and B cell 
receptor (BCR), that are able to specifically recognize molecular structures (antigens) present 
in pathogens. Therefore each particular cell expresses a unique receptor and together the 
lymphocyte system provides an immense repertoire of different receptors able to detect 
and eliminate any potential infection. 
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2. B cell differentiation and antibody diversification 
B cell differentiation allows the generation of B cells carrying a functional BCR. The BCR, 
or antibody in its secreted form, is a multiproteic complex comprised by a membrane-
bounded immunoglobulin responsible for antigen recognition and a heterodimer Igα/Igβ 
that is involved in the signal transduction. Signaling through this receptor modulates a 
number of aspects of B cell biology.  
Immunoglobulins are compound of two pairs of identical chains, called light chain (IgL) 
and heavy chain (IgH). The N-terminal region of both IgL and IgH constitute the variable 
region of the antibody, involved in antigen recognition. The C-terminal region of the IgH 
chain encodes the constant region of the antibody, which determines the elimination 
pathway of the antigen. 
The variable region of the immunoglobulin is composed of numerous gene segments, 
which encode the variable (V), diversity (D) and, in the case of IgH, joining (J) exons. The 
constant region is formed by eight gene segments (Cµ, Cδ, Cγ1, Cγ2a, Cγ2b, Cγ3, Cε and Cα) 
which code for different constant regions.  
2.1. Early B cell differentiation and primary antibody diversification  
The genetic information encoded in the immunoglobulin genes is not enough to explain 
their high diversity. The diversification of immunoglobulins is achieved in two stages. During 
the process of B cell development in the bone marrow, there is a first mechanism of 
antibody diversification called V(D)J recombination. This antigen-independent process is a 
site specific recombination reaction, mediated by the recombinase activating gene (RAG) 
complex, between recombination signal sequences (RSS) that flank each of the V, D and J 
gene segments.  RAG recombinases initiate the reaction by introducing a double strand DNA 
break in the RSS of each of the sequences to be joined. This break is repaired by the non-
homologous end-joining (NHEJ) pathway, generating a gene unit composed by one of each 
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VDJ segments. During the VDJ recombination, the diversification in the immunoglobulin 
repertoire arises from the aleatory selection of the different VDJ segments and the inexact 
joining of the different regions during the repair mediated by the NHEJ pathway.  This 
process generates a primary repertoire composed by 105-106 specificities (reviewed in 
(Bassing et al., 2002)). 
2.2. Late B cell differentiation and secondary antibody diversification  
B cells that have successfully rearranged their immunoglobulin genes by V(D)J 
recombination express IgM/IgD in their membrane and migrate to the periphery where the 
antigen-encounter triggers a secondary diversification of the antibody. This second step in 
antibody maturation occurs in secondary lymph organs in structures called germinal centers 
(GC) and is essential to generate high-affinity antibodies.  
Secondary antibody diversification in GCs comprises two molecular reactions, called SHM 
and CSR. SHM introduces point mutations in the DNA encoding the variable region of the Ig. 
These mutations generate a collection of related B cell clones from which those with 
increased affinity for the cognate antigen are positively selected by affinity maturation 
(reviewed in (Di Noia and Neuberger, 2007)). CSR is a region-specific recombination that 
involves the replacement of the Cµ or Cδ (which code for the IgM or IgD heavy chains), 
primary expressed, by downstream constant regions Cγ, Cε or Cα (which code for the IgG, 
IgE or IgA heavy chains). CSR allows the combination of the same N-terminal region of the 
antibody with different C-terminal regions, thus diversifying the effector capabilities of Ig of 
a given antigen specificity (reviewed in (Xu et al., 2012)). Although molecularly different, 
both SHM and CSR are triggered by the action of the same enzyme, activation-induced 
deaminase (AID) (Muramatsu et al., 2000). Details about AID action will be discussed below.  
Secondary diversification in GCs can give rise to 1012-1013 BCR specificities and thus 
fundamental for the production of high-affinity antibodies and for a proper immune 
response.  
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3. Germinal Centers 
GCs emerge in follicles present in secondary lymphoid organs, and involve intense cell 
proliferation and cell death, derived from the clonal expansion and affinity maturation 
processes. While absolutely required for a proper immune response, GCs are a prone 
environment to malignant transformation; indeed, the vast majority of lymphoid neoplasms 
originate from GC B cells (reviewed in (Kuppers, 2005)).   
Secondary lymphoid organs are structured in follicles composed mostly by naïve B cells 
that are surrounded by T cells. After antigen encounter, naïve B cells migrate to the T rich 
zone of follicles in secondary lymph organs, where they are fully activated by its interaction 
with specificity-matching CD4+ T cells. This interaction is mediated mainly by CD40, a 
member of the TNF receptor family expressed by B cells, with the CD40 ligand (gp39) 
expressed in T cells. B cells thus activated can give rise directly to short-lived antibody-
secreting cells or enter the GC program.  
The initiation of the GC reaction involves an intense process of cell proliferation that 
allows the clonal expansion of the cell that recognized the antigen. At the same time, B cells 
diversify their immunoglobulin genes by SHM (see below) and generate a pool of clones with 
different affinities. B cell clones will be selected based on their affinity for the initiating 
antigen by signals emanating from their surface Ig (BCR) in the context of Tfh and dendritic 
cells. Ultimately, further rounds of proliferation, SHM and selection will lead higher affinity 
variants to terminally differentiate into memory B cells or antibody secreting plasma cells 
(reviewed in (Victora and Nussenzweig, 2012)), The exit of the GC reaction involves a switch 
in the transcriptional program that halts cell cycle progression, as well as Ig diversification, 
and allows the differentiation to antibody secreting plasma cells (PC), the effector cells of 
the humoral response, and memory B cells (Figure 1).  
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Figure 1. Germinal Center dynamics. In the periphery, naive B cells that have successfully undergone 
V(D)J recombination and express a functional B cell receptor can enter the GC reaction after antigen 
encountering. Naïve B cells become fully activated after interacting with Th cells. This activation 
triggers the aggregation and the clonal expansion of B cells, fan initiates the GC reaction. In the GC, B 
cells proliferate and remodelate their Ig genes by SHM and CSR and generate clones with higher 
affinity for the antigen that triggered the reaction by affinity maturation (see text for more details).  
3.1. Transcriptional regulation of the Germinal Center 
A number of key transcription factors have been associated with the initiation, 
maintenance and exit of the GC reaction. c-Myc is expressed in hyperproliferative 
populations of GC B cells both in immature and mature GCs and it is essential for GC 
formation and maintenance (Calado et al., 2012). When GCs are established, Bcl-6 is 
considered the master regulator of their transcription program maintenance. Indeed, Bcl-6 
deficient mice do not generate GCs or high affinity antibodies and conversely, Bcl-6 
overexpression increases GC formation. Bcl-6 is a transcriptional repressor that directly 
suppresses p53 expression, and through its binding to PIAS2, suppresses also the activation 
of the cell cycle-arrest gene p21. Thus, the transcriptional program modulated by Bcl-6 
might allow the high proliferation rate present in GC B cells as well as tolerance to DNA 
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damage (reviewed in (Basso and Dalla-Favera, 2010)) (Figure 2). Other factors are involved in 
the maintenance of proliferation. EZH2 expression in mature B cells is restricted to GC B cells 
and is required for full GC development by promoting B cell proliferation and preventing 
their terminal differentiation, by inhibiting Blimp-1 (Caganova et al., 2013).  In addition, E2A, 
a basic helix-loop-helix transcription factor, promotes cell cycle progression by inducing 
CCND3 and E2F2, and by downregulating RB1 (Schmitz et al., 2012).  
The exit from the GC and the generation of antibody secreting PC involves a switch of the 
transcriptional program and requires the downregulation of Bcl-6, which acts repressing 
Blimp-1, a master regulator of the PC program. Blimp-1 expression is necessary to mediate 
plasma cell differentiation (Shapiro-Shelef et al., 2003) by silencing genes that specify B cell 
identity, such as surface B cell markers, B cell activation markers, B cell-associated 
transcription factors and genes induced in BCR signaling. It also represses CIITA, which leads 
to the downregulation of MHC class II genes and antigen presentation (Piskurich et al., 2000, 
Silacci et al., 1994, Shaffer et al., 2002) (Figure 2).  In addition, Blimp-1 downregulates genes 
involved in cell proliferation, partly by directly repressing c-Myc.  
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Figure 2. Germinal center and plasma cell transcriptional program. Master regulators of the 
Germinal center (Bcl6) and the Plasma cell (Blimp-1) programs are depicted. In the text boxes below, 
the main biological processes controlled by these factors are summarized. Among the pathways 
controlled by Bcl6, immunoglobulin remodeling through CSR and SHM, as well as cell cycle 
progression and replication can be highlighted. On the other hand, Blimp-1 is responsible of the 
differentiation to antibody secreting cells, favoring all the processes involved in protein synthesis and 
processing.   
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4. CCCTC-binding factor 
CCCTC-binding factor (CTCF) is a highly conserved protein ubiquitously expressed in 
higher eukaryotes (Klenova et al., 1993). It contains a conserved 11 zinc finger DNA-binding 
domain by which it interacts with 50000-65000 sites in mammalian genomes  (Chen et al., 
2012). CTCF was initially described by Lobanenkov and colleagues as a DNA-binding protein 
involved in the regulation of the chicken c-myc gene (Lobanenkov et al., 1990). A later work 
carried by Filippova and colleagues defined CTCF as a multivalent factor by its flexibility in Zn 
finger usage in the interaction with the chicken and human c-myc promoter, and showed 
that it repressed c-myc transcription (Filippova et al., 1996). Initially, analysis of CTCF activity 
in a particular promoter using reporter transgenes suggested that CTCF acted as a barrier to 
transcription progression (Kellum and Schedl, 1991). Later on, CTCF was shown to block 
enhancer activity when placed between enhancers and promoters, indicating that CTCF 
binding sites could act as transcriptional insulators (Giles et al., 2010, Phillips and Corces, 
2009). However, recent genome-studies suggest that CTCF could determine the 
establishment of functional expression domains, rather than act as a physical chromatin 
barrier (Handoko et al., 2011). The use of Chromosome Conformation Capture Carbon Copy 
(5C) has revealed the existence of long-range interactions that include enhancers, promoters 
and CTCF-binding sites. CTCF binding to these sites did not promote physically insulation of 
gene domains; rather, a proportion of these sites were enriched in active transcription 
marks (Sanyal et al., 2012). Several evidences support that interaction between promoters 
and enhancers is the main activity for CTCF. For example, transcriptional activation of the 
major histocompatibility complex II (MHC II) is preceded by a DNA looping event that allows 
the interaction between the XL9 enhancer and its cognate promoter. This looping has been 
shown to be mediated by CTCF, the MHC class II transactivator (CIITA) and specific 
transcription factors (Majumder and Boss, 2010, Majumder et al., 2008). CTCF has also been 
involved in the regulation of the transcription of the human protocadherin gene A (PDAC) 
cluster, which contains a number of exons that are stochastically expressed by alternative 
promoters. Promoter choice is mediated by CTCF-cohesin DNA looping, which forms and 
active chromatin hub. The binding of CTCF to the promoters preceding each exon correlated 
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with the level of gene activity (Golan-Mashiach et al., 2012, Kehayova et al., 2011, Guo et al., 
2012, Hirayama et al., 2012, Monahan et al., 2012). All these evidences support the role of 
CTCF as a general transcriptional regulator, by mediating long-range interactions between 
promoters and distal enhancers.  
4.1. CTCF in B cells 
CTCF is a fundamental factor controlling the process of B cell differentiation in the bone 
marrow, mainly by controlling the process of V(D)J recombination. The first evidences of the 
role of CTCF in the regulation of V(D)J came from the identification of a regulatory region 
located between V and D clusters, called IGCR1, that underwent CTCF-mediated looping to 
bring together promoters and enhancers. This looping was shown to be required for 
balancing the Ig repertoire and to enable the orderly D to J followed by V to DJ 
recombination stages (Guo et al., 2011). Additional evidences supporting the relevance of 
CTCF in balancing the Ig repertoire came from an additional study, where they showed that 
CTCF depletion early during B cell development blocked differentiation, mainly by impairing 
both the germline transcription of the different V and J regions, and cell proliferation 
(Ribeiro de Almeida et al., 2011).  Additionally, in this context,  CTCF has been pointed as an 
important mediator  of the IgH locus looping required for V(D)J recombination (Degner et al., 
2011, Medvedovic et al., 2013, Gerasimova et al., 2015).  
However the role of CTCF at later stages of B cell development has not been addressed. 
Given the complex transcriptional regulation involved in GC initiation, maintenance and exit 
and the chromatin remodeling events associated with secondary antibody diversification, we 
hypothesized that CTCF is very likely to play a regulatory role in these events.  
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5. Activation-induced deaminase 
AID was first identified by Honjo’s lab, as a cDNA upregulated in a B cell line (CH12F3) 
upon in vitro induction of CSR (Muramatsu et al., 1999). Later studies showed that AID is 
absolutely required for CSR and for SHM in mouse and human, where AID inactivating 
mutations give rise to Hyper IgM 2 immunodeficiency syndrome (Muramatsu et al., 2000, 
Revy et al., 2000). Given its similarity with Apobec-1, an enzyme responsible of the 
apolipoprotein-B mRNA editing, AID was initially hypothesized as an RNA cytidine deaminase 
that edits mRNA. However, several subsequent studies showed that AID deaminates 
cytosines present in single-strand DNA (ssDNA), but not in double-strand DNA (dsDNA), 
mRNA or DNA-RNA hybrids (Chaudhuri et al., 2003, Maul et al., 2011, Petersen-Mahrt et al., 
2002, Pham et al., 2003, Ramiro et al., 2003, Bransteitter et al., 2003, Dickerson et al., 2003). 
AID initiates both SHM and CSR by deaminating dC generating deoxyuraciles (dU), thus 
turning C:G pairs into U:G mismatches. The final nucleotide substitution or the generation of 
a DSB in the case of CSR, depends on the recognition and subsequent processing of the U:G 
lesion.  DNA replication before DNA repair causes a transition mutation from a C:G pair to 
T:A pair. Recognition of the U:G lesion by the mismatch repair pathway can result in the 
mutation of nearby A:T pairs, possibly with the contribution polymerase ζ activity. 
Alternatively, U can be excised by the uracyl DNA glycosilase (UNG) generating an abasic site 
that can be replicated by trans-lesion polymerases giving rise both transitions and 
transversions on the DNA (reviewed in (Di Noia and Neuberger, 2007)). On the other hand, 
the abasic site can also be cleaved by the apurinic/apyrimidinic (AP) endonucleases, which 
results in ssDNA breaks or dsDNA breaks if the abasic sites are close enough on opposite 
strands of the DNA, thus generating the recombination substrates for CSR. The breaks 
generated in the two participating switch regions are synapsed in a process that requires the 
participation of several proteins, including histone 2A family-member X (H2AX), p53 binding 
protein 1 (53BP1), ataxia telangiectasia mutated (ATM), and completed by the fusion of the 
two DSBs possibly by the NHEJ pathway, although this has not been unequivocally proven 
(reviewed in (Chaudhuri and Alt, 2004)).  
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5.1. Regulation of AID expression  
AID activity entails the introduction of mutations and DSBs on the DNA and thus it can 
potentially endanger genome instability and promote oncogenic lesions (see below). A 
number of regulatory mechanisms are thought to contribute to an optimal balance of AID 
function to allow an efficient immune response while preventing collateral damage:  
1. Transcriptional regulation. AID is encoded by the Aicda gene. Aicda expression is 
mostly, but not absolutely, restricted to activated B cells (see below). Aicda 
expression is triggered by cytokines and cell-cell interactions associated to antigen-
activation of B cells during the GC reaction. Four conserved regulatory regions in the 
Aicda gene carry canonical binding sites for at least 19 transcription factors, both 
activators and repressors of its transcription (reviewed in (Stavnezer, 2011)). Thus, 
the combination of expression of the repressor proteins and transcriptional 
activators restricts Aicda expression to activated B cells.  
2. Post-transcriptional regulation. The 3’-untranslated region (3’-UTR) of the AID mRNA 
carries binding sites for at least two miRNAs, miR-181b and miR-155. miR181b is 
downregulated soon after B cell activation, but increases later on during in vitro 
culture. miR-181b overexpression in splenic B cells downregulates AID mRNA and 
protein by directly binding to its 3’ UTR (de Yebenes et al., 2008). On the other hand, 
miR-155 expression parallels AID expression in activated B cells. Mutation of the 
miR155-binding site in AID increased both AID mRNA and protein (Dorsett et al., 
2008, Teng et al., 2008). Thus, miR181b and miR-155 seem to coordinately ensure 
the optimal level of AID during B cell activation.  
3. Post-translational regulation. Regulation of subcellular localization, proteosomal 
degradation and phosphorylation all seem to contribute to the levels and activity of 
AID protein.  AID shuttles between the nucleus and the cytoplasm (Brar et al., 2004, 
Ito et al., 2004, McBride et al., 2004), being actively retained in the cytoplasm and 
excluded from the nucleus (Methot et al., 2015). AID compartmentalization also 
determines protein stability, thus is destabilized in the nucleus by ubiquitin 
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dependent and independent pathways (Aoufouchi et al., 2008, Uchimura et al., 
2011). Regarding phosphorylation, at least three positions have been defined to 
affect AID activity when phosphorylated, both in vitro and in vivo (McBride et al., 
2008, Basu et al., 2005).  
5.2. AID target specificity and lymphomagenesis 
AID activity is mostly, although not exclusively, restricted to Ig genes during B cell 
activation. However, the mechanisms that determine the sequence specificity of AID -or 
targeting- remain mostly unknown. Long before the identification of AID, it was noticed that 
SHM preferentially accumulated on short DNA motifs in the variable region of the Ig genes 
that conformed to the WRCY/RGYW consensus (Dorner et al., 1998, Rogozin and Kolchanov, 
1992). Later studies using biochemical assays showed that AID preferentially mutates 
cytosines included in WRC motifs (Bransteitter et al., 2004, Pham et al., 2003). Thus, AID 
activity has preference for DNA hotspots both in vitro and in vivo. However, the low 
complexity of AID hotspots cannot account for the preference of AID for Ig genes, suggesting 
that additional mechanisms are involved in defining AID target specificity.  
The best-established requirement for AID activity is the transcriptional activation of the 
target sequence (Peters and Storb, 1996).The frequency of mutations in SHM has been 
shown to be proportional to the transcriptional rate in B cells (Rada and Milstein, 2001, 
Fukita et al., 1998, Bachl et al., 2001) and transcription of the switch region involved in CSR is 
associated and required for the reaction to take place(Jung et al., 1993, Stavnezer-Nordgren 
and Sirlin, 1986). Transcription is thought to allow the generation of ssDNA structures, either 
as transcription bubbles (Ramiro et al., 2003, Chaudhuri et al., 2003) or R-loops (Yu et al., 
2005) that might facilitate AID accessibility to its substrate. In addition, recent studies have 
postulated that RNA polymerase II and the elongation factor Spt5 might be involved in the 
recruitment of AID to the transcribed genes (Pavri et al., 2010, Yamane et al., 2011). 
However, transcription is not enough to define an AID target, given the high number of 
transcribed genes during the GC reaction that do not accumulate AID mutations (Liu et al., 
2008, Shen et al., 1998). Indeed, although a number of non-Ig genes are known to be targets 
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of AID (Liu et al., 2008, Pasqualucci et al., 2001), they do so at a much lower frequency -in 
the range of one hundredth lower- than Ig genes, which does not necessarily correlate with 
their transcription rate. Some recent works have proposed that AID targeting can be 
restricted to regions of noncoding RNA transcription that might recruit AID to these single-
strand DNA-forming sites (Pefanis et al., 2014). In addition, AID recruitment seems to occur 
in regions with converging sense and antisense transcription (Meng et al., 2014), although 
these claims need to be further explored. In summary, most of the mechanisms proposed to 
restrict AID targeting are related directly or indirectly with transcriptional regulation. 
Regardless of molecular basis of AID specificity, it is well accepted that the presumably 
rare off-target events of AID activity can have oncogenic impact.  Specifically, AID can 
promote mutations and DSB followed by chromosomal translocations in other regions of the 
genome (Liu et al., 2008, Robbiani et al., 2009, Ramiro et al., 2006, Ramiro et al., 2004, 
Robbiani et al., 2008). Chromosomal translocations are the hallmark of mature B cell 
lymphomas, the most frequent of all human lymphomas. AID depletion delays the onset of 
lymphomagenesis (Kovalchuk et al., 2007, Pasqualucci et al., 2008, Ramiro et al., 2004), 
establishing a direct link between AID off target activity and oncogenic transformation in B 
cells (Figure 3).  
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Figure 3. AID activity in Germinal Centers. In mature B cells, Ig heavy chain gene (depicted in the 
upper panel) is composed of a productive rearrangement of the 3’ variable region (yellow square) 
and a 5’ region that comprises a number of constant regions (small squares) each of which is 
preceded by a highly-repetitive non-coding switch region (small circles). The recognition of the 
antigen triggers a secondary diversification of the immunoglobulin in the germinal center by SHM 
and CSR. During SHM, point mutations (black lines) are introduced in the variable region of the Ig. 
CSR is a site specific recombination that generates antibodies with isotypes alternative to IgM/IgD 
(IgG1 is depicted in the figure). Both reactions are initiated by the deamination of citosines in the 
variable or the switch region of the Ig gene by AID.  On the other hand, AID can also have a 
pathogenic activity by promoting chromosomal translocation (Myc-Ig translocation depicted), as well 
as mutations in proto-oncogenes and other non-Ig genes.  
5.3. AID expression and activity in non-B cells 
Although initially considered B cell specific, Chiba’s lab provided the first evidence that 
AID can be induced in epithelium under inflammatory conditions (Matsumoto et al., 2007). 
In this study, the authors showed in humans that infection of gastric epithelium with cag+ H. 
pylori induced aberrant AID expression. In addition, in vitro TNF-α treated gastric cell lines 
expressed AID via NF-κB pathway. Subsequent studies carried on by this group showed AID 
expression in patients with chronic hepatitis or cirrhosis (Kou et al., 2007), as well as the 
induction of its expression in vitro by treatment with TNF-α in different cell types, such as 
hepatocytes, colon and cholangiocarcinoma-derived cells (Endo et al., 2007, Endo et al., 
2008, Komori et al., 2008). In addition, the authors provided evidences of accumulation of 
nucleotide alterations in different oncogenes such as p53 and c-myc, presumably triggered 
by AID activity.  
All these works have fostered the idea that the expression and activity of AID can be 
broader than initially foreseen and furthermore it has been suggested that AID can link the 
presence of inflammation with the development of cancer (Figure 4), particularly in the 
epithelial context. However, this hypothesis has not been directly tested with appropriate in 
vivo models.  
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Figure 4. Connection between inflammation and aberrant AID activity in epithelium. Inflammatory 
cues and viral or bacterial infections might trigger AID activation through NF-κB. In a context of 
inflammation, where there is an increase in cell proliferation and survival, AID might promote 
malignant transformation through the accumulation of mutations and chromosomal translocations. 
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GCs are microstructures where Ig genes diversify through SHM and CSR and their function is 
fundamental to generate a proper immune response. Thus, understanding the biology of this 
reaction, as well as the regulation of AID, has been the general objective of the present 
work. We defined two specific objectives: 
 
 
1. To explore the involvement of CTCF in the GC reaction using a conditional knock-out 
mouse model. 
 
 
2. To determine the role of AID in the development of carcinomas by the generation of 
conditional knock-in mouse models for AID overexpression in colon and pancreas.  
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Mice and treatments 
Mice of both genders were used unless specified otherwise. All animals were housed 
in the Centro Nacional de Investigaciones Cardiovasculares animal facility under a 12-h 
light/dark cycle with food ad libitum.  
Number of animals per group to detect biologically significant effect sizes was 
calculated using appropriate statistical sample size formula and indicated in the biometrical 
planning section of the animal license submitted to the governing authority. Blinding and 
randomization was not applicable to the animal studies. All animal procedures conformed to 
EU Directive 2010/63EU and Recommendation 2007/526/EC regarding the protection of 
animals used for experimental and other scientific purposes, enforced in Spanish law under 
RD 53/2013. 
Conditional mouse model for AID expression in pancreas and colon 
R26AID mice were generated by insertion of a construct encoding mouse AID cDNA 
into the Rosa26 IRES-GFP targeting vector (Nyabi et al., 2009). AID cDNA was PCR-amplified 
from C57BL/6 mice (primers: forward 5’-TTCTGTGAAGACCGCAAGGCT-3’; reverse 5’-
CCCTTCCCAGGCTTTGAAA-3’), cloned into the pENTR/D-TOPO Gateway vector (Invitrogen), 
and subsequently recombined into the Rosa 26 targeting vector, in which the cloned 
construct is preceded by a loxP-flanked transcriptional stop cassette and followed by an 
internal ribosomal entry site and GFP. The construct was linearized with PvuI before 
electroporation into hybrid 129/C57BL/6 ES cells. Clones positive for homologous 
recombination in the Rosa26 locus were identified by Southern blot of EcoRV-digested 
genomic DNA hybridized with a 5’-arm Rosa26 probe. R26AID mice were crossed with Villin-
CRE+/KI (el Marjou et al., 2004) mice and p48-CRE+/KI (Kawaguchi et al., 2002) mice to 
promote expression of AID in colonic and pancreatic epithelial cells, respectively.  
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AID deficient mice 
Balb/c AID-/- mice were generated by backcrossing AID-/- mice (Muramatsu et al, 
2000) for 6 generations by speed congenics (Ramiro et al, 2004). Briefly, mice were 
backcrossed into the wild type Balb/c strain, genotyping each generation for 136 
polymorphic markers that distinguished between Balb/c and the original C57BL/6 or CBA/J 
background.  
DSS-induced Colitis Associated Cancer (CAC) experiments 
8-10-week-old Balb/c AID+/- and AID-/- (Ramiro et al, 2004) mice were given 3% 
dextran sulfate sodium salt (DSS, Sigma) in their drinking water for 5 days followed by 
regular drinking water for 10 days.  Colon samples were obtained from these mice after 10 
cycles of DSS treatment, and Swiss roll preparations were fixed, embedded in paraffin for 
section and stained with hematoxilin/eosin. 
CTCF deficient mice 
Conditional knockout CTCFfl/fl; AID-CRE+/TG (or controls CTCF+/fl; AID-CRE+/TG) mice 
were obtained by crossing CTCFfl/fl mice (Heath et al., 2008) with AID-CRE+/TG (Kwon et al., 
2008), to allow the specific depletion of CTCF in GC B cells. 
T-dependent immunization of CTCF deficient mice 
T-dependent immunization was induced in 6-11 weeks CTCFfl/fl; AID-CRE+/TG or 
CTCF+/fl; AID-CRE+/TG mice by intravenously injection of 108 sheep red blood cells. 
Immunization response was analyzed in spleen seven days after injection.  
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Histological characterization 
Immunohistochemistry 
Pancreas and colon samples from aged mice were fixed in neutral-buffered 10% 
formalin solution (Sigma-Aldrich), embedded in paraffin blocks, and cut in 5 µM sections. 
Hematoxilin/eosin staining was performed using standard protocols. For 
immunohistochemistry, sodium citrate buffer (10mM Sodium citrate buffer (Sigma-Aldrich), 
pH=6) was used for antigen retrieval. Endogenous peroxidases were blocked with 3% (v/v) 
H2O2 (Merk) in Methanol (Sigma-Aldrich). The following antibodies were used: polyclonal 
rabbit anti-human CD3 (Dako, 1/200), rabbit anti-Ki67 (Abcam, 1/100), and biotinylated goat 
anti-rabbit (Abcam, 1/200). Primary antibodies were incubated overnight at 4 °C. 
Biotinylated secondary antibodies were incubated 1 hour at room temperature. Biotinylated 
antibodies were detected with the ABC system using diaminobenzidine as substrate (Vector 
Laboratories). Images were acquired with a Leica DM2500 microscope fitted with a 20X 
magnification lens. Reactive cells from 10 microscope fields per pancreas were counted 
using ImageJ software.  
Immunofluorescence 
Pancreas and colon specimens were fixed with 4% paraformaldehyde, incubated with 
30% sucrose, embedded in OCT compound (Olympus) and frozen in dry ice. 10 µM sections 
were permeabilized (PBS 1X, 0.5% (v/v) Triton) and blocked with Image-It FX signal enhancer 
(Invitrogen, Molecular Probes). The following antibodies were used: rabbit anti-GFP (Abcam, 
1/100), rat anti-mouse CD8α (BD Pharmigen, 1/100), goat anti-rabbit Alexa Fluor 488 
(Molecular Probes, 1/500) and goat anti-rat Cy3 (Jackson ImmunoResearch, 1/500). Slides 
were mounted with Vectashield mount medium containing DAPI (Vector Laboratories).  
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Cell culture 
Primary B cells 
Primary B cells were obtained from CTCFfl/+ AID-CRETG/+ or CTCFfl/fl AID-CRETG/+. 
Complete spleens were dispersed in a 70 um mesh in complete RPMI. Next, erythrocytes 
were lysed using erythrocyte lysis buffer (ACK Lysing Buffer, BioWhittaker) for 4 minutes at 
room temperature. After washing with cold complete RPMI, B cells were isolated by 
immunomagnetic depletion using anti-CD43 (Miltenyi Biotec). When indicated, cells were 
labeled with 1 µM of the cell tracer CFSE (Invitrogen). Purified B cells were cultured at a final 
concentration of 1.2 x 106 cells/ml in complete RPMI supplemented with 50 µM of 2-
βMercaptoetanol (Gibco), 20 mM Hepes (Gibco). When indicated, 10 ng/ml of IL4 
(PeproTech) and 25 µg/ml lipopolisacarid (LPS, Sigma-Aldrich), 25 µg/ml LPS (Sigma-Aldrich), 
or 10 µg/ml of anti-mouse IgM (Jackson Immunoresearch) and 1 µg/ml of anti-mouse CD40 
(BD Pharmigen) were added. Cells were analyzed at different time points by flow cytometry.  
Colon and pancreas cell lines 
Human pancreatic and colon adenocarcinoma cell lines PaTU-8988S, AsPC-1, LoVo 
and SW480 cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) , 
HEPES (10 mM), penicillin (50 U/ml) and streptomycin (50 µg/ml). TNF-α (50 ng/ml) (Sigma-
Aldrich) was added when indicated.  
Pancreas explants 
Primary pancreatic acinar cells were isolated and cultured as described in (Gout et al., 
2013). Briefly, R26AID+/KI; p48-CRE+/KI or control R26AID+/+; p48-CRE+/KI mice were sacrificed 
by hypoxia in CO2 camera, and pancreas was extracted and conserved in cold Hank’s 
Balanced Saline Solution (Gibco). Complete pancreas was mechanically and enzymatically 
digested with collagenase IA (Sigma-Aldrich) to obtain isolated acinar structures. Acini were 
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grown in Waymouth’s medium supplemented with 2.5% FBS, HEPES (10 mM), trypsin 
inhibitor (0.25 mg/ml) (Sigma-Aldrich) and recombinant human epidermal growth factor (25 
ng/ml) (Sigma-Aldrich). After 24 hours of culture, cells were transferred to a collagen-coated 
(Type I collagen, Beckton Dickison) plate. After 48 hours, non-attached cells were removed 
and culture cell medium was replaced every three days.  
NK killing assay in vitro  
Primary pancreatic acinar cells from R26AID+/+ p48-CRE+/KI and R26AID+/KI p48-CRE+/KI 
mice were isolated as described above. Acinar cells were isolated from 6-days culture and 
individualized by trypsinization. NK cells were isolated by cell sorting from wild-type C57BL/6 
mice. Both male and female aged 6 to 8 week-old were used as NK cells donors. NK cells and 
acinar pancreatic cells were co-cultured for 4 hours in the presence of IL2 (2000 U/ml, 
Peprotech) at a 1:10 (target cell: NK effector cell) ratio. 
DNA damage analysis in pancreas explants 
y-H2AX staining and Opera acquisition  
Primary pancreatic acinar cells were grown on 96 well plates (Perkin Elmer), and y-
H2AX (Millipore, 1/500) immunofluorescence was performed using standard procedures. 
Images were automatically acquired from each well with the Opera High-Content Screening 
System (Perkin Elmer). A 40x magnification lens was used and pictures were taken at non-
saturating conditions. Images were segmented using DAPI staining to generate masks 
matching cell nuclei, and the mean per-cell y-H2AX signal was calculated.  
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Gene expression analysis 
Messenger RNA analysis by quantitative RT-PCR 
RNA was extracted from colon samples with Trizol (Invitrogen), according to 
manufacturer protocol. RNA from pancreas samples was extracted with GTC solution, 
following a standard phenol-chloroform protocol (reagents from Sigma-Aldrich), followed by 
DNAse treatment (Qiagen). RNA from cell pellets was extracted using RNeasy Mini Kit 
(Qiagen), according to manufacturer protocol, and followed by DNAse treatment (Qiagen). 
cDNA was synthesized from 100-600 ng of initial RNA, using Random Hexamers (Roche) and 
SuperScript II reverse transcriptase. mRNA was quantified by SYBR green assay (Applied 
Biosystems), with normalization to GAPDH. Amplification was performed in 7900HT Fast 
Real-Time PCR System (Applied Biosystems) equipment. Primers used are shown in table 1. 
Messenger RNA analysis by Droplet digital PCR  
Each 20 µl ddPCR reaction contained 10 µl of 2x ddPCR Supermix (Bio-Rad), 1 µl of 
cDNA generated from 1.4 µg of RNA, and 500 nM of each primer and 250 nM Taqman probe 
(Table 1). After droplet generation, a mean of 12,000 droplets were obtained per sample.  
Samples were transferred into a 96 well plate (Eppendorf) and cycled in a thermal 
cycler (Bio-Rad) under the following conditions: 95 °C for 10 minutes followed by 38 cycles 
of 94 °C for 30 seconds, 58 °C for 1 minute and a final step at 98 °C for 10 minutes. After 
amplification, samples were transferred to a droplet reader (QX100 Droplet Digital PCR, Bio-
Rad) from which positive-drop data were extracted with Quantasoft software.  
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Oligonucleotide Sequence (5’-3’) 
Human-AID 
Sense AAA TGT CCG CTG GGC TAA GG 
Antisense GGA GGA AGA GCA ATT CCA CGT 
Human-GAPDH 
Sense GAA GGT GAA GGT CGG AGT C 
Antisense GAA GAT GGT GAT GGG ATT TC 
Mouse-AID 
Sense ACC TTC GCA ACA AGT CTG GCT 
Antisense AGC CTT GCG GTC TTC ACA GAA 
Mouse-GAPDH 
Sense TGA AGC AGG CAT CTG AGG G 
Antisense CGA AGG TGG AAG AGT GGG AG 
Pan-RAE 
Sense TGG ACA CTC ACA AGA CCA ATG 
Antisense CCC AGG TGG CAC TAG GAG 
Pan-RAE-FAM probe CCA TGA TTT ATC CGC AAA GCC AGG GCC 
Elastase1 
Sense GCA CAG CAT CTT TTG TTT GGG TAA 
Antisense GGG GAC AGT GGT CTA CTC TCT 
Elastase2a 
Sense ACG AGT CCA GGA CAA TCA GAG A 
Antisense TGA TAA GGC CAC TCA TAA AAA GGA 
P53 
Sense AGC GAC TAC AGT TAG GGG GC 
Antisense AAC CAA GTA ATC CAG AAA AAT AAG A 
PRDM1 
Sense GCA AAG AGG TTA TTG GCG T 
Antisense TGT AGA CTT CAC CGA TGA GG 
CTCF 
Sense CAC CTG GGT CCT AAC AGA ACA GA 
Antisense AGT ATG AGA GCG AAT GTG TCG TTT 
 
Table1. Oligonucleotides used in sequencing, ddPCR and qRT-PCR. 
 
RNA sequencing 
For RNAseq library preparation, 500 ng of total RNA were used to generate barcoded 
RNAseq libraries using the TruSeq RNA sample preparation kit v2 (Illumina). Briefly, poly A+ 
RNA was purified using poly-T oligo- attached magnetic beads using two rounds of 
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purification followed by fragmentation and first and second cDNA strand synthesis. Next, 
cDNA 3’ ends were adenylated and the adapters were ligated followed by PCR library 
amplification. Finally, the size of the libraries was checked using the Agilent 2100 Bioanalyzer 
DNA 1000 chip and their concentration was determined using the Qubit® fluorometer (Life 
Technologies). Libraries were sequenced on a HiSeq2500 (Illumina) to generate 60 bases 
single reads. FastQ files for each sample were obtained using CASAVA v1.8 software 
(Illumina).   
Sequencing reads were pre-processed by means of a pipeline that used FastQC 
(Krueger et al., 2011), to asses read quality, and Cutadapt (Criscuolo and Brisse, 2014) to 
trim sequencing reads, eliminating Illumina adaptor remains, and to discard reads that were 
shorter than 30 bp. The resulting reads were mapped against the mouse transcriptome 
(GRCm38, release 76; aug2014 archive) and quantified using RSEM v1.17 (Li and Dewey, 
2011). Data were then processed with a diferential expression analysis pipeline that used 
Bioconductor package EdgeR (Robinson et al., 2010) for normalization and diferential 
expression testing. 
CTCF protein detection 
Spleen hCD2 positive B cells were sorted from LPS/IL4 or CD3/CD28 cultures after 
48h of stimulation. For CTCF immunoblotting, cell pellets were incubated on ice for 20 min in 
RIPA lysis buffer in the presence of protease inhibitors (Roche) and lysates were cleared by 
centrifugation. Total protein was sized-fractioned by SDS-PAGE on 8% acrylamide-
bisacrylamide gel and transferred to Protan nitrocellulose membrane (Whatman) in transfer 
buffer (0.19M glycine, 25 mM Tris base and 0.01% SDS) containing 20% methanol. Gels were 
transferred for 45 min at 0.4A. Membranes were probed with anti-mouse CTCF (1/2500, 
Bethyl laboratories) and anti-mouse-tubulin (1/5000, Sigma-Aldrich). Then, membranes 
were incubated with corresponding HRP-conjugated antibodies (Dako) and developed with 
Amesham ECL Western Blotting Detection Reagent (GE Healthcare Life Sciences). 
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DNA Sequencing 
Sanger sequencing 
DNA was extracted from pancreatic tissue following an standard 
phenol:chloroform:Isoamyl Alcohol (25:24:1) protocol. Precipitation was performed in 
ethanol, using the Pellet Paint co-precipitant (Novagen), according to manufacturer 
protocol.  
Amplification was carried out with 2.5 U of Pfu Ultra (Stratagene)  in a 50 µl reaction, 
containing 200 ng of genomic DNA, following the profile: 94 °C- 5 minutes, 25 cycles a 94 °C- 
10 seconds, 60 °C-30 seconds, y 72 °C-1 minute. Primers used are shown in Table 1. The 
amplified fragment was isolated from 1% agarose gel and purified in column (illustra GFXTM 
Gel Band Purification Kit), following manufacturer protocol. Purified fragment was cloned in 
the pGEM-T Easy vector and sequenced using the SP6 primer. The sequences obtained were 
analyzed for the presence of mutations with the program Seqman (Lasergen).  
Next generation sequencing for detection of mutations 
DNA from three R26AID+/+; p48-CRE+/KI and three R26AID+/KI; p48-CRE+/KI was 
extracted and amplified following the conditions used in Sanger sequencing. Primers used 
for amplification are depicted in Table 1. After amplification, equimolar quantities of DNA 
from each mouse were pooled. The amplification products were fragmented in 100-300 bp 
fragments using Covaris S2 shearing instrument.  Specific adapters were added to each 
sample to its identification. Next, samples were purified using the Agencourt AMPure XP 
(Beckman Coulter Genomics) kit, following manufacturer instructions. To generate the 
libraries, 10 additional cycles of amplification were performed using specific oligonucleotides 
provided by Illumina, with the Phusion High-Fidelity polymerase (Finnzymes). Purified 
libraries were sequenced in Genome Analyzer IIx (Illumina), using the SBS TruSeq v5 
reactives, following manufacturer instructions. Lectures with a quality Q<20 were excluded. 
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The good-quality sequences were aligned Novoalign (Novocraft technologies) and were 
processed with SAMtools (Li et al., 2009). In order to obtain a table in excel format with all 
the mutations obtained, the results were parsed with a specific program designed in Perl.  
Flow cytometry  
Lymphoid tissues analysis in CTCF deficient mice 
CTCFfl/fl; AID-CRE+/TG and CTCF+/fl; AID-CRE+/TG were sacrificed by hypoxia in CO2 
camera and Peyer’s Patches, spleen and femur were extracted, and conserved in RPMI-1640 
(Sigma-Aldrich) supplemented with 10% FBS and penicillin (50 U/ml) and streptomycin (50 
µg/ml) (thereafter complete RPMI). Peyer’s patches and spleens were dispersed in a 70 mm 
mesh in complete RPMI and cell suspension obtained were centrifuged (10’/400 x g/ 4°C). 
Bone marrow cells were obtained by perfusion with complete RPMI through femur channel. 
The spleen and bone marrow cell suspensions obtained were centrifuged and erythrocytes 
were lysed using erythrocyte lysis buffer (ACK Lysing Buffer, BioWhittaker) for 4 minutes at 
room temperature. After lysis, cells were washed with complete RPMI and resuspend in PBS 
1X-2% FBS. 
Cells obtained from Peyer’s Patches, spleens and bone marrows were stained with 
antibodies conjugated to different fluorochromes or to biotin. Cells were centrifuged (10 
min/400xg/4°C) and resuspended in PBS 1X- 2% FBS and the antibody combination indicated 
in each case. Cells were incubated on ice for 20 min, washed with PBS 1X- 2% FBS and 
centrifuged (10 min/400xg/4°C). When direct antibodies were used, cells were resuspend in 
PBS 1X- 2% FBS for its analysis by flow cytometry. When biotin-conjugated antibodies were 
used, cells were incubated in a second step with streptavidin conjugated to the 
corresponding fluorchrome in PBS 1X- 2% FBS, as indicated before. Next, cells were washed 
with PBS 1X- 2% FBS, centrifuged (10 min/400xg/4°C) and resuspend in PBS 1X- 2% FBS. Cells 
were stained with the appropriate combination of the antibodies shown in table 2. Data 
were acquired in LSRFortessa (BD Biosciences) and analyzed with the FlowJo software. 
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Cell cycle analysis in CTCF deficient primary B cells 
Primary B and T cells cultured for different time points were harvested, washed with 
PBS 1X-2% FCS, and incubated with Hoescht during 1 hour at 37°C. After incubating with 
Hoescht, membrane was stained with the appropriated combination of antibodies (Table 2). 
Data were acquired in LSRFortessa (BD Biosciences) and analyzed with the FACSDiva 
software (BD Biosciences). 
 Pancreas explant flow cytometry 
 RAE detection: Acinar cells were isolated and individualized from 6-days explant 
cultures. Cells obtained from the cultures were centrifuged (3 min/300xg/4°C) and 
resuspended in HBSS 1X- 2% FBS and the anti-mouse RAE purified antibody. Cells were 
incubated on ice for 20 min, washed with HBSS 1X- 2% FBS and centrifuged (3 
min/300xg/4°C). Cells were incubated in a second step with secondary antibody conjugated 
to Alexa Fluor-647 (Life Technologies) in HBSS 1X- 2% FBS, as indicated before. Next, cells 
were washed with HBSS 1X- 2% FBS, centrifuged (3 min/300xg/4°C) and resuspend in HBSS 
1X- 2% FBS.  
 Analysis of NK killing assay: After 6 days of culture, acinar cells were trypsinized and 
stained with CFSE, in order to distinguish them from NK cells. Acinar cells were cultured in 
presence of NK cells for 4 hours. Reaction was stopped by introducing culture plates on ice. 
Total cells were directly stained with DAPI, to detect the presence of death cells. Data are 
presented as the proportion of CFSE+DAPI+ cells normalized to the same population in 
cultures lacking NK cells. 
Statistics 
Statistical analyses were performed with GraphPad Prism (version 6.01 for Windows, 
GraphPad Software, San Diego, CA, USA) using two-tailed Student’s t-test. P ≤ 0.05 was 
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considered statistically significant. Error bars in figures represent standard error of the mean 
(SEM). Normal distribution of data was assessed by applying a D’Agostino & Pearson 
omnibus normality test. F-test was used to compare variances between groups. For the 
survival analyses, GraphPad Prism was used and the Mantel–Cox test was applied. 
Differences were considered statistically significant at P ≤ 0.05. For the correlation analysis 
performed, D’Agostino & Pearson omnibus normality test was applied. As samples did not 
follow a Gaussian distribution, non-parametric Spearman correlation analysis was 
performed.  
 
 
 
 
 
  
Antibody Company Fluorochrome 
B220 (CD45R) BD Horizon Brilliant Violet 
CD21 BD Biosciences FITC 
CD93 eBioscience APC 
CD5 BD Biosciences FITC 
IgD BD Biosciences FITC 
IgM Invitrogen PE 
CD25 BD Biosciences APC 
Fas BD Biosciences PE 
GL7 BD Biosciences FITC 
 
 
 
 
 
  
Antibody Company 
CD23 BD Biosciences 
CD43 BD Biosciences 
CD19 BD Biosciences 
IgA BD Biosciences 
IgG1 BD Biosciences 
Fluorochrome Company 
PE-Cy7 BD Biosciences 
Fluorochrome-conjugated antibodies Biotin-conjugated antibodies 
Streptavidin 
Table 2. Antibodies used in FACS analysis 
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1. Analysis of the role of CTCF during the Germinal Center 
reaction 
Transition through the different stages of the GC and PC differentiation involves the 
coordinated expression of gene networks. Bcl-6  is the master regulator of the GC reaction 
and acts as a transcriptional repressor to control genes involved in activation, survival, DNA-
damage response and cell cycle arrest, among others pathways (Reviewed in (Basso and 
Dalla-Favera, 2010)). Bcl-6 also plays an important role in preventing plasma cell 
differentiation by the repression of Blimp-1. In turn, Blimp-1 was firstly described as a factor 
sufficient to drive plasma cell differentiation (Turner et al., 1994) and is considered the key 
factor controlling transition from GC B cells to antibody-secreting plasma cells (Shapiro-
Shelef et al., 2003, Shaffer et al., 2002), by its ability to repress cell proliferation and to 
establish the PC program. CTCF is a ubiquitously expressed chromatin remodeler and 
proposed to have a general role in the control of gene transcription (reviewed in (Ong and 
Corces, 2014)). In B lymphocytes, a number of studies have shown the relevance of CTCF 
during B cell development. In particular, CTCF is a key regulator of VDJ recombination and B 
cell differentiation, by promoting the interaction between different V exons (Garrett et al., 
2005, Degner et al., 2011, Guo et al., 2011, Ju et al., 2011, Volpi et al., 2012, Medvedovic et 
al., 2013, Lin et al., 2015, Ribeiro de Almeida et al., 2011, Ribeiro de Almeida et al., 2012). 
However, the role of CTCF in mature B cells, and particularly in the context of B cell 
activation in GCs, has not been addressed. 
1.1. CTCFfl-AIDCRE TG B cells develop normally 
To address the role of CTCF during the germinal center (GC) reaction we specifically 
depleted CTCF in GC B cells by crossing mice carrying a floxed CTCF allele (CTCFfl mice) with 
transgenic AID-CRE mice (AID-CRETG/+), where the Cre recombinase is inserted together with 
a cDNA encoding the human CD2 molecule (hCD2) in a BAC construct that contains the 
complete AID locus (Figure 5A). Thus, in CTCFfl/fl;AID-CRETG/+ mice (CTCFfl/fl hereafter for 
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simplicity) the expression of CRE and the deletion of CTCF is induced concomitantly with the 
expression of AID -therefore specifically expressed in GC B cells- and can be followed by the 
surface expression of the hCD2 (Figure 5B). In all the experiments CTCFfl/+ AID-CRETG/+ mice 
were used as control (CTCFfl/+ mice).  
 
Figure 5. Conditional depletion of CTCF in GC B cells. Mouse model used to specifically remove CTCF 
in GC B cells. A) Schematic of the constructs used for conditional depletion of CTCF in GC B cells. Mice 
carrying the CTCF allele flanked by LoxP sites (top) were crossed with transgenic AID-CRE mice 
(bottom), where a cassette coding for Cre recombinase and the hCD2 receptor is inserted in an AID-
BAC. B) Analysis of hCD2 expression in GCs B cells (GL7+) in Peyer’s Patches from CTCFfl/+ mice. 
We first analyzed B cell differentiation in bone marrow and the subsequent 
maturation that takes place in spleen, where immature B cells differentiate into transitional 
(T), marginal zone (MZ) and follicular (FO) mature B cells,  of CTCFfl/fl and CTCFfl/+ control 
mice (Figure 6, 7). The analysis of B cell populations both in bone marrow and spleen did not 
showed any difference between CTCF deficient and control mice. We can conclude that the 
depletion of CTCF promoted by AID-Cre recombinase does not affect B cell differentiation. 
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Figure 6. CTCF depletion in GC B cells does not affect B cell differentiation in the bone marrow. 
B cell differentiation was analyzed by FACS in the bone marrow from CTCFfl/fl and CTCFfl/+ control 
mice. A) Quantitative FACS analysis of B cell differentiation in bone marrow. The different 
populations were defined as: preproB (B220+ CD19-); preB (B220+CD19+CD25+IgM-); proB 
(B220+CD19+CD25-IgM-); Immature (B220+CD19+CD25-IgM+); Recirculating (B220+CD19+IgD+). B) 
Quantification of all the populations shown in (A), measured as the percentage of each 
population referred to total B220+ cells. All data are values +/- Standard Deviation (CTCFfl/+, white 
dots; CTCFfl/fl; black dots). Statistical analysis was done with two-tailed unpaired Student’s t test. 
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Figure 7. CTCF depletion in GC B cells does not affect B cell differentiation in the spleen. B cell 
differentiation was analyzed by FACS in the spleen from CTCFfl/fl and CTCFfl/+ control mice. The 
different populations were defined as: Marginal Zone (MZ: B220+CD21++CD23+); Follicular (FO: 
B220+CD21+CD23++CD93-); Transitional (T: B220+CD21+CD23++CD93-). Quantifications are shown on 
the right, measured as the percentage of each population referred to total B220+ cells. All data are 
values +/- Standard Deviation (CTCFfl/+, white dots; CTCFfl/fl; black dots). Statistical analysis was done 
with two-tailed unpaired Student’s t test. 
1.2. CTCF is required for the GC reaction 
To evaluate the impact of CTCF depletion in GC B cells we first analyzed the 
constitutive GC response in the Peyer’s Patches (PPs) of CTCFfl/fl and CTCFfl/+ control mice 
(Figure 8). We measured the presence of Fas+GL7+ B cells by FACS, and found that in CTCF 
deficient mice the GC B cell population is dramatically reduced (3.8 ± 0.6% in CTCFfl/+ mice 
versus 0.57±0.1% in CTCFfl/fl mice) (Figure 8, upper plots). In addition, we observed that CTCF 
deficient mice lack almost completely IgA switched B cells (3.88±0.4% in CTCFfl/+ mice versus 
1.03±0.2% in CTCFfl/fl mice) (Figure 8, middle plots). The analysis of the Cre reporter gene 
hCD2 showed a clear population of hCD2 positive cells in control mice, whereas this 
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population was almost absent in CTCF deficient mice (5.48±0.5% in CTCFfl/+ mice versus 
0.8±0.2% in CTCFfl/fl mice) (Figure 8, bottom plots). These results suggest that CTCF is 
required for the GC reaction in vivo. 
 
Figure 8. CTCF is required for the constitutive GC reaction. Quantitative FACS analysis of GL7, Fas, 
IgA and hCD2 expression in Peyer’s Patches B cells from CTCFfl/+ (n=4) and CTCFfl/fl (n=3) mice. Top: 
Fas+GL7+ B cells. Middle: B220+IgA+ total live lymphocytes. Bottom: B220+hCD2+ total live 
lymphocytes. Quantifications are shown on the right, measured as percentage of each population 
referred to total B220+ cells. p(FasGL7)= 0.0056; p(IgA)= 0.0015; p(hCD2)= 0.0008. All data are values 
+/- Standard Deviation (CTCFfl/+, white dots; CTCFfl/fl; black dots). Statistical analysis was done with 
two-tailed unpaired Student’s t test. 
To determine the role of CTCF in de novo GC, we immunized CTCFfl/fl and CTCFfl/+ mice with 
sheep red blood cells (SRBC) and analyzed the GC response in spleen 7 days after 
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immunization (Figure 9A). Quantification of GC B cells (Fas+GL7+) and IgG1-switched cells by 
FACS showed that both populations were reduced in the absence of CTCF (FasGL7: 3.03 ± 0.4 
in CTCFfl/+ mice versus 0.1 ± 0 CTCFfl/fl mice; IgG1: 0.42 ± 0.06 in CTCFfl/+ mice versus 0.02 ± 
0.02 in CTCFfl/fl mice). In addition, immunohistochemistry staining revealed that CTCF 
deficient mice lack Bcl6 positive B cells (Figure 9B), a marker of GC B cells. Together, these 
results showed that CTCF is required for both constitutive and de novo GC reactions. 
 
Figure 9. CTCF is required for de novo GC reaction. A) FACS analysis of GL7, Fas, IgG1 and hCD2 
expression in splenic B cells from CTCFfl/+ (n=6) and CTCFfl/fl (n=5) mice 7 days after SRBC 
immunization. Top: Fas+GL7+ B cells. Middle: B220+IgG1+ total live lymphocytes. Bottom: B220+hCD2+ 
total live lymphocytes. Quantifications are shown on the right, measured as percentage of each 
population referred to total B220+ cells. p(FasGL7)= 0.0001; p(IgG1)= 0.0005; p(hCD2)= 0.0001. B) 
Representative Pax5 (top) and Bcl6 (bottom) immunohistochemistry of spleen from CTCFfl/+ and 
CTCFfl/fl mice after 7 days of SRBC immunization. All data are values +/- Standard Deviation (CTCFfl/+, 
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white dots; CTCFfl/fl; black dots). Statistical analysis was done with two-tailed unpaired Student’s t 
test. 
1.3. CTCF depletion differentially affects B cells under different stimuli conditions 
To address the molecular mechanisms of GC impairment in CTCF deficient mice we 
made use of an standard in vitro system in which LPS/IL4 stimulation of naïve B cells allows 
recapitulating many features of the GC reaction such as induction of B cell proliferation, AID 
expression, γ 1 switch region transcription and CSR . Splenic B cells coming from CTCFfl/fl or 
control mice were stimulated with LPS/IL4 and the B cell activation was tracked by the 
expression of the hCD2 reporter. Surprisingly, we did not find any difference in the 
proportion of hCD2 positive cells between CTCF deficient and control mice (82.84±2.4% in 
CTCFfl/+ cells and 84.31±3.8% in CTCFfl/fl cells)   (Figure 10A, B). To rule out that the absence of 
phenotype could be due to a defective deletion of the CTCF allele, we first measured CTCF 
protein by WB in sorted hCD2+ B cells from LPS/IL4 cultures (Figure 10C). We observed a 
reduction of more than 80% of CTCF protein in CTCFfl/fl mice. In addition, we measured CTCF 
mRNA levels, both by qRT-PCR and RNA-sequencing, and observed a significant reduction in 
CTCFfl/fl compared with control mice (Figure 10D). The discrepancy observed between in vivo 
and in vitro effect after CTCF depletion suggests that LPS and IL4 cannot recapitulate 
faithfully GC B cell activation in vivo and bypasses the need of activated B cells for CTCF. 
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Figure 10. CTCF is not required for LPS/IL4-mediated B cell activation in vitro. In vitro activation of 
splenic B cells from control and CTCF deficient mice was analyzed in LPS/IL4 for different time points. 
A) Analysis of hCD2+ in LPS/IL4 stimulated splenic B cells from control and CTCF deficient mice at 48h 
and 72h. B) Percentage of hCD2+ cells at the different time points analyzed. n(CTCFfl/+)=11; 
n(CTCFfl/fl)=10. C) CTCF Western Blot in hCD2+ purified B cells from control and CTCF deficient mice 
after 72 hours of stimulation with LPS/IL4. CTCF amount normalized to GAPDH is shown. D) CTCF 
mRNA quantification by qRT-PCR (p=0.0283) and by RNA-seq (p=0.0003). All data are values +/- 
Standard Deviation (CTCFfl/+, white dots; CTCFfl/fl; black dots). Statistical analysis was done with two-
tailed unpaired Student’s t test. 
To address this issue, we sought for in vitro stimulation conditions that could 
reproduce more closely B cell activation in vivo. B cells can be stimulated in vitro by T cells in 
the presence of immobilized anti-CD3 together with soluble anti-CD28 (Klaus et al., 1994, 
Johnson-Leger et al., 1998, Klaus et al., 1999). To allow B cell stimulation in the absence of 
LPS/IL4, we co-cultured them with CD3/CD28 stimulated T cells in a 1:1 ratio. When we 
measured the levels of hCD2 to track B cell activation we observed that after 72 and 96 
hours of stimulation, the population of hCD2 positive cells was significantly reduced in the 
CTCF deficient samples compared with control mice (72h: 17.34 ± 2.7 in CTCFfl/+ cells versus 
10.71 ± 1.09 in CTCFfl/fl cells; 96h: 23.67 ± 2.7 in CTCFfl/+ cells versus 15.33 ± 1.4 in CTCFfl/fl 
cells)  (Figure 11A, B). Quantification of CTCF protein in hCD2+ cells by WB revealed a similar 
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level of depletion to the observed in LPS/IL4 cultures (Figure 11C), which agreed with a 
significant reduction in the CTCF mRNA level, both by qRT-PCR and RNA-sequencing (Figure 
11D). Thus, despite similar levels of CTCF depletion, B cell stimulation by LPS and IL4 is 
refractory to CTCF loss, while B cell activation in the presence of T cells requires CTCF.  These 
results indicate that the stimulation pathway might determine the susceptibility of B cells to 
CTCF deficiency, and that T-B co-culture might better recapitulate B cell stimulation in GCs.  
 
 
Figure 11. CTCF is required for CD3/CD28 activated B cells in T-B co-culture. A) Analysis of hCD2+ in 
CD3/CD28 T-B co-cultures from control and CTCF deficient mice at 48h and 72h. B) Percentage of 
hCD2+ cells at the different time points analyzed. n(CTCFfl/+)= 7;n(CTCFfl/fl)= 7. p(72h)= 0.0438; 
p(96h)= 0.0187. C) CTCF Western Blot in hCD2+ purified B cells from control and CTCF deficient mice 
after 72 hours of stimulation with CD3/CD28. Normalized CTCF amount relative to GAPDH is shown. 
D) mRNA CTCF quantification by qRT-PCR (p= 0.0059) and by RNA-seq (p= 0.0002). All data are values 
+/- Standard Deviation (CTCFfl/+, white dots; CTCFfl/fl; black dots). Statistical analysis was done with 
two-tailed unpaired Student’s t test.  
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1.4. In vitro T-B co-culture better mimics in vivo stimulation 
To understand the differential requirement for CTCF of B cells under different 
activation cues we analyzed the transcriptional profile of CTCF proficient B cells stimulated 
with LPS and IL4 and B cells stimulated with CD3/CD28 T cells and compared them with in 
vivo activated GC B cells. For that, we performed RNA-seq of isolated Fas+GL7+ GC B cells 
from PPs, of hCD2+ B cells isolated from CD3/CD28 T cell cultures or hCD2+ cells isolated 
from LPS/IL4 cultures. Each of these samples was compared with RNA-seq from resting 
splenic B cells in triplicates and the three pairwise comparisons were first analyzed with 
Venn diagrams (Figure 12). We observed that all the three stimulation conditions shared a 
high proportion of both downregulated and upregulated genes, suggesting that in vitro 
activation conditions properly recapitulate many of the events that take place in vivo. In 
addition, we found that CD3/CD28 T cell stimulated and LPS/IL4 stimulated B cells shared 
12% of their transcriptional programs. However, we observed that CD3/CD28 T stimulated B 
cells and GC B cells shared a specific set of 267 downregulated genes (8.89%, shaded area 1), 
whereas LPS/IL4 stimulated B cells only shared 97 unique downregulated genes (3.29% 
shaded area 2) with GC cells (Figure 12A). Similar results were found for upregulated genes 
(Figure 12B). 
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Figure 12. In vitro B cell stimulation through T cells recapitulates the GC reaction.   RNA-seq analysis 
was performed in GC B cells from Peyer’s Patches (GC) and hCD2+ sorted B cells from WT mice 
stimulated for 48h in the CD3/CD28 T-B co-culture (CD3) or LPS/IL4 (LPS) and data were compared 
pairwise with those obtained from resting B cells. Overlaps of downregulated (A) or upregulated (B) 
genes across all three conditions are depicted in Venn diagrams. Percentage of the common 
downregulated (A) or upregulated (B) genes between GC and CD3/CD28 or between GC and LPS/IL4 
(shaded areas 1-4) is shown. Statistical analyses were done with two-tailed chi-square analysis. p-
value < 0.00001. 
In order to analyze in more detail the differences between stimulations, we selected the 10% 
most differentially expressed genes between GC and resting B cells, and plotted the Z-score of these 
genes in all stimulation conditions (resting, LPS/IL4 stimulated, GC and CD3/CD28 T stimulated B 
cells). Importantly, this analysis revealed that the highest similarity between GC and CD3/CD28 
stimulated cells occurred in genes related with cell cycle, a key feature of the GC reaction (Figure 
13A). This concept is reflected in the analysis of individual genes (Figure 13B). 
 
 
Results 
 
 
66 
 
 
Figure 13. Transcriptional comparison of GC B cells, LPS/IL4 and CD3/CD28 stimulated B cells. A) 
Heatmap of 10% more differentially expressed genes between resting and GC cells. The scale bar 
indicates z-scores of gene expression values for resting, GC and LPS/IL4 and CD3/D28 stimulated B 
cells. Clustering was performed using the average linkage method based on Pearson correlation 
distance. Each column represents an independent replicate. Pathway enrichment analysis of gene 
clusters is shown on the right. B) Expression profile of selected genes. Unchanged genes are 
represented in the square. 
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These data suggest that co-culturing B cells together with T cells recapitulates the in vivo 
GC transcriptional program better than the standard LPS/IL4 stimulation, which in turn could 
explain the differential requirement for CTCF of B cells stimulated under these conditions. 
1.5. CTCF transcriptionally regulates key processes of GC biology 
To further characterize the role of CTCF in the GC reaction, and given the unfeasibility 
to obtain CTCF deficient cells in vivo, we decided to analyze the transcriptional differences 
between CTCF deficient and control mice in both in vitro stimulation conditions. To that end, 
we performed RNA-seq analysis of hCD2 positive splenic B cells from CD3/CD28 T or LPS/IL4 
cultures. Comparison of CTCF deficient and proficient cells from CD3/CD28 T cultures, 
revealed differentially expressed 2229 genes (adjusted p-value<0.05) of which 
approximately half were upregulated (1154) and half were downregulated (1064) (Figure 
14A). In sharp contrast, only 50 genes were differentially expressed in CTCF deficient versus 
proficient cells from LPS/IL4 cultures (Figure 14A). This notion was reinforced when 
analyzing the Z-scores of the 20% most differentially expressed genes between CTCF 
deficient and control CD3/CD28 T stimulated cells (Figure 14B, Annex). Together, these data 
agree with the finding that CTCF is dispensable for LPS/IL4 stimulated B cells but required for 
CD3/CD28 T stimulated B cells and for GC B cells. 
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Figure 14. CTCF deficiency differentially affects B cells under different stimulation conditions. RNA-
seq analysis was performed in hCD2+ sorted B cells stimulated for 48h in the presence of CD3/CD28 T 
or LPS/IL4. A) Number of genes differentially transcribed between CTCFfl/fl and control samples in 
LPS/IL4 or CD3/CD28 conditions. Red: upregulated genes; green: downregulated genes. B) Heatmap 
of the 20% genes most differentially expressed between CTCFfl/fl and CTCFfl/+ B cells after CD3/CD28 T 
stimulation. The scale bar indicates z-scores of gene expression values for CTCFfl/fl or CTCFfl/+ samples 
in LPS/IL4 and CD3/CD28 stimulation conditions. Clustering was performed using the average linkage 
method based on Pearson correlation distance. Each column represents an independent replicate. 
The functional relevance of the genes affected by CTCF depletion is revealed by the 
finding that most of the genes controlled by CTCF (75,7%, CTCFfl/fl versus CTCFfl/+ CD3/CD28 T 
stimulated B cells) are part of the GC transcriptional program in vivo (Figure 15A). 
Importantly, we observed that almost 65% of these common genes (1095 out of 1688) 
negatively correlated when comparing fold change expression (Figure 15B). This result 
suggests that CTCF might be involved in the regulation of a significant number of genes 
involved in the GC reaction. 
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Figure 15. CTCF regulates expression of GC-related genes A) Overlap between genes differentially 
expressed in GC reaction (RNA-seq from WT PPs GC B cells versus WT resting B cells) and genes 
differentially expressed upon CTCF depletion in CD3/CD28 T stimulated B cells (RNA-seq from CTCFfl/fl 
versus CTCFfl/+ hCD2+ sorted cells). B) Fold change expression profile of differentially expressed genes 
in GC reaction in vivo compared with resting B cells and in CD3/CD28 stimulated CTCFfl/fl B cells 
compared with control samples. Percentage of genes in each quadrant is shown. 
Pathway enrichment analysis of the genes differentially expressed upon CTCF 
depletion showed enrichment in terms included in the p53 pathway, B cell receptor 
signaling, hematopoietic cell lineage and cell cycle (Figure 16), among others.  
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Figure 16. CTCF regulates B cell signaling and cell cycle genes in GC B cells. KEGG pathway 
enrichment analysis of genes differentially expressed in CD3/CD28 T stimulated CTCFfl/fl versus 
CTCFfl/+ B cells. 
Analysis of the individual genes present in each pathway (Figure 17) revealed that 
CTCF depletion impairs downregulation of Pirb (CD85A), Cr2 (CD21), Fcgr2b (CD32), Pik3r5 
(P101) and Ppp3ca (Calcineurin A Alpha),  genes, involved in the B cell signaling pathway. On 
the other hand, CTCF seems to be involved in the upregulation of E2f3, Tfdp1, Ccnb1 (Cyclin 
B1), Cdc25a, Wee1, Ccne2 (Cyclin E2) and Cdk6, key players of cell cycle progression. This 
result further highlights the relevance of CTCF as a transcriptional regulator of events critical 
for the GC reaction. 
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Figure 17. CTCF deficiency alters the expression of genes involved in key pathways in GC B cells. 
Log fold change (LogFC) representation of the genes included in the KEGG pathways analyzed in 
Figure 16. Black, GC versus resting B cells fold change. Orange, CTCFfl/fl versus CTCFfl/+ CD3/CD28 T 
stimulated splenic B cells fold change. 
1.6. CTCF deficient cells recapitulate key features of plasma cells 
One of the main features of the GC B cells is their high proliferation rate (MacLennan, 
1994, Allen et al., 2007) required for the generation of large numbers of different Ig variants 
that undergo affinity-based selection. Our transcriptome results indicate that numerous 
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genes involved in cell cycle progression are not properly upregulated in CTCF deficient cells. 
To address whether cell cycle progression was indeed affected by the lack of CTCF we 
performed Hoechst staining of CD3/CD28 T stimulated CTCFfl/fl and control cells. Indeed, we 
observed a reduced proportion of S/G2 phase CTCFfl/fl cells (42.8% ± 2.4%) when compared 
with control cells (52.9% ± 2.4%), as well as an increase in the proportion of G1 phase CTCF 
deficient cells (55.2% ± 2.5% in CTCFfl/fl cells versus  44.7% ± 2.7% in CTCFfl/f+ cells) (Figure 
18A, B). 
 
Figure 18. CTCF deficiency impairs cell cycle. A) FACS cell cycle analysis in CD3/CD28 T stimulated 
CTCFfl/+ (n=4) and CTCFfl/fl (n=5) hCD2+ cells.  Percentages of G1 and S/G2 phases are shown on the 
right. p(G1)=  0.0242; p(S/G2)= 0.0221. Statistical analysis was done with two-tailed unpaired 
Student’s t test. 
Transition from naïve to GC B cells involves the activation of a gene-expression 
program that drives cell proliferation and Ig gene remodeling. In contrast, the transition 
from GC B cells to antibody secreting PCs involves a transcriptional switch that promotes a 
halt in cell proliferation to allow cell differentiation. To address whether the maintenance of 
the GC transcriptional program could be compromised in CTCF deficient cells, we analyzed 
the shifts in PC transcriptional program (fold change PC/GC (Shi et al., 2015) in the selected 
genes previously found to be affected by CTCF depletion. In contrast to our data on the 
naïve to GC transition (Figure 15B) we found a positive correlation between those genes 
changed at the transition from GC to PC and the ones that are altered upon CTCF depletion. 
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Specifically, about 60% of the genes analyzed were expressed in the same direction in both 
conditions (Figure 19A) and about 40% showed anti-correlative expression. Thus, CTCF 
depletion seems on one hand to counter balance the GC transcriptional program, and on the 
other, to favor the plasma cell transcriptional program. Among the genes commonly 
upregulated in CTCF deficient and plasma cells, we found the master transcriptional 
regulator of the plasma cell differentiation program, Blimp-1 (PRDM1) (Shapiro-Shelef et al., 
2003, Shaffer et al., 2002), the plasma cell marker Syndecan-1 and Ig genes, whose 
expression is greatly increased in antibody secreting cells. Interestingly, a major category of 
genes whose expression shifts in the GC to PC transition was cell-cycle genes. Analysis of 
individual genes included in this category showed a sharp downregulation both at the GC to 
PC transition and in CTCF deficient cells (Figure 19B). These results suggested that CTCF 
depletion in mature B cells might impair the maintenance of the GC program, promoting the 
premature acquisition of plasma cells features, such as the upregulation of transcriptional 
repressor Blimp-1 (confirmed by qRT-PCR, Figure 19C). In support of this notion, we found 
that Myc and CIITA, two known Blimp-1 targets, were downregulated in CTCF deficient B 
cells (Figure 19D). 
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Figure 19. CTCF deficient cells prematurely express plasma cell genes. A) Fold change expression 
profile of differentially expressed genes in PC in vivo compared with GC B cells and in CD3/CD28 T 
stimulated CTCFfl/fl B cells compared with control samples. Percentage of genes in each quadrant is 
shown. B) Log fold change (LogFC) representation of cell cycle-related genes. Purple, PC versus GC B 
cells fold change. Orange, CTCFfl/fl versus CTCFfl/+ CD3/CD28 T stimulated splenic B cells fold change. 
C) qRT-PCR analysis of Blimp-1 expression in CD3/CD28 T stimulated CTCFfl/+ and CTCFfl/fl hCD2+ cells. 
p= 0.008. D) RNA-seq analysis of Myc and CIITA expression in CD3/CD28 stimulated CTCFfl/+ and 
CTCFfl/fl hCD2+ cells for 48h. p(Myc) = 0.009; p(CIITA)= 0.006. All data are values +/- Standard 
Deviation (CTCFfl/+, white dots; CTCFfl/fl; black dots). Statistical analysis was done with two-tailed 
unpaired Student’s t test. 
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1.7. CD40 signaling restores cell proliferation and Blimp-1 levels in CTCF deficient 
cells 
Blimp-1 is essential for plasma cell differentiation both by extinguishing cell 
proliferation and by triggering the antibody secretion program. In turn, signaling through the 
CD40 receptor has been shown to downregulate Blimp-1 levels in B cells (Randall et al., 
1998, Knodel et al., 2001, Upadhyay et al., 2014). Thus, we reasoned that if Blimp-1 
upregulation were responsible for the proliferation defect found in CTCF deficient cells we 
could possibly rescue this phenotype by CD40 signaling. We cultured B cells in the presence 
of T cells stimulated with CD3/CD28 for 24 hours and then added anti-CD40 or left them 
untreated (Figure 20A). qRT-PCR analysis confirmed once again that CTCF deficient B cells 
have higher Blimp-1 levels than their littermate controls (Figure 20B). Importantly, this effect 
was dampened in cells treated with anti-CD40 (Figure 20B) (2.93±0.3 in CTCFfl/fl cells versus 
1.40±0.4 in CTCFfl/fl+CD40 cells).  
 
Figure 20. CD40 signaling downregulates Blimp-1 in CTCF deficient cells. CTCFfl/+ and CTCFfl/fl splenic 
B cells stimulated with CD3/CD28 T cells were treated with anti-CD40 antibody. A) Experimental 
approach. B) Analysis of Blimp-1 mRNA by qRT-PCR in hCD2+ CTCFfl/+ or CTCFfl/fl cells after 48 hours 
with or without anti-CD40 treatment. p(***)=  0.0001, p(*)= 0.0159. Mean values +/- Standard 
Deviation are shown. Statistical analysis was done with two-tailed unpaired Student’s t test. 
Next, we determined the proportion of B cells in the CD3/CD28 T cells cultures after 48h of 
treatment with anti-CD40 (Figure 21A, B). We observed that, in the absence of anti-CD40, 
the proportion of CTCF deficient B cells is reduced when compared with control samples (left 
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panel) (42.2% ± 4.2% in CTCFfl/+ cells versus 22.4% ± 3.1% in CTCFfl/fl cells). However, in the 
presence of anti-CD40, this difference is attenuated (37.7% ± 4.5% in CTCFfl/fl cells versus 
49% ± 7% in CTCFfl/+ control cells; p=0.2) (right panel). 
 
 
Figure 21. CD40 signaling partially rescues CTCF deficiency. Analysis of B cell proportions in B-T 
CD3/CD28 co-cultures after 24 or 48 hours of anti-CD40 treatment. A) Representative FACS staining 
showing B cell population at 48h without (left) or with anti-CD40 treatment (right). B) Quantification 
of B220 proportion at different time-points after CD40 treatment. p(**)= 0.0063, p(*)= 0.023. Mean 
values +/- Standard Deviation are shown. Statistical analysis was done with two-tailed unpaired 
Student’s t test. 
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Finally, we analyzed the cell cycle in these cells (Figure 22A, B). As shown above, we 
found that CTCFfl/fl cells have a lower proportion of cycling cells than CTCFfl/+ cells from 
littermate controls (35.7%±3.7% versus 21%±2.2%). In contrast, we observed that after 
treatment with anti-CD40, the proportion of S/G2 cells was not significantly reduced 
(p=0.07) in CTCFfl/fl (28.5 ± 1) compared with control samples (37 ± 4.3) (right panel). These 
results indicate that signaling through the CD40 receptor is able to partially rescue the cell 
cycle impairment associated with CTCF deficiency, presumably through the downregulation 
of Blimp-1. 
 
Figure 22. Cell cycle analysis in B-T CD3/CD28 co-cultures after 24 or 48 hours of anti-CD40 
treatment. A) Representative FACS staining showing cell cycle at 48h of CD40 treatment. B) 
Quantification of proliferating cells at different time-points after CD40 treatment. p(**)= 0.0083, 
p(*)=  0.0126.  Mean values +/- Standard Deviation are shown. Statistical analysis was done with two-
tailed unpaired Student’s t test. 
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2. Analysis of the contribution of AID to the formation of 
epithelial neoplasias 
AID initiates both SHM and CSR by deaminating cytosines in the variable (SHM) or the 
switch (CSR) region of the immunoglobulins. However, its activity is not completely 
restricted to the immunoglobulin genes, and it can promote mutations and DSB followed by 
illegitimate chromosomal translocations in other regions of the genome. 
In addition, in the last years, the expression of AID has been shown to be not restricted 
to activated B cells, as initially believed. AID expression has been reported in several tissues, 
including gastric, hepatic and gut epithelia (Endo et al, 2007; Endo et al, 2008; Matsumoto et 
al, 2007) reviewed in (Marusawa et al, 2011). In these tissues, the expression of AID has 
been associated with inflammatory contexts and the activation of the NF-κB pathway (Endo 
et al, 2007) (Matsumoto et al, 2007), and has been claimed to promote the accumulation of 
mutations in epithelial cells (Matsumoto et al, 2007; Matsumoto et al, 2010; Takai et al, 
2009) reviewed in (Marusawa et al, 2011). Given that chronic inflammation in epithelial 
tissues predisposes to cancer development (Mantovani et al, 2008), the finding that the 
mutagenic activity of AID can be induced in an inflammatory context has fostered the idea 
that AID might contribute to or even constitute the link between inflammation and cancer 
(Takai et al, 2012) reviewed in (Marusawa et al, 2011).  
Several gain-of-function mouse models have been generated to address the contribution 
of AID to neoplastic transformation. Ubiquitous AID overexpression was shown to lead 
mostly to early T cell neoplasia (Okazaki et al, 2003), among other malignancies. In contrast, 
B-cell-specific AID overexpression mouse models did not result in lymphomagenesis (Muto 
et al, 2006; Robbiani et al, 2009) unless the tumor suppressor p53 was removed (Robbiani et 
al, 2009).  Regarding the role of AID in the development of epithelial neoplasias, different 
studies have made use of ubiquitous AID overexpression mouse models or in vitro assays, 
but the role of AID expression in epithelial tissues has not been specifically addressed. 
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2.1. Inflammation-induced AID does not contribute to carcinogenesis  
Induction of AID expression in inflammatory conditions has been proposed as a 
mechanism to explain the link between inflammation and cancer development. As 
inflammation plays a critical role in the etiology of colorectal and pancreatic ductal 
adenocarcinoma (reviewed in (Vonderheide and Bayne, 2013, Feagins et al., 2009)), we 
decided to focus on these two tissues to study the contribution of AID to the formation of 
neoplasias. To investigate whether inflammatory conditions promote AID expression in 
these tissues, we treated human epithelial cell lines derived from colorectal adenocarcinoma 
(LoVo and SW480) and pancreatic adenocarcinoma (AsPC and PaTU) with the pro-
inflammatory cytokine TNF-α and measured AID expression by qRT-PCR. TNF-α stimulation 
increased AID mRNA expression in all cell lines analyzed (Figure 23A, B). To assess whether 
primary, non-transformed cells were also able to express AID in response to inflammatory 
stimuli, we generated explants from mouse pancreatic acinar cells and treated them with 
TNF-α. As with the human tumor cells, mouse primary epithelial cells expressed AID upon 
exposure to TNF-α (Figure 23C). TNF-α treatment typically induced 4-30 fold increases in AID 
mRNA levels in the different cell types tested, consistent with previous findings in liver, 
gastric and colorectal cell lines (Endo et al., 2007, Endo et al., 2008, Matsumoto et al., 2007). 
Together, these data confirm previous results showing that inflammatory stimuli can trigger 
AID expression in cell lines originated from human colorectal adenocarcinoma (Endo et al., 
2008), and show that pancreatic adenocarcinoma cells and primary pancreatic cells are also 
responsive to TNF-α treatment.  
Inflammation-induced AID expression has been proposed to contribute to or even be the 
leading cause of some epithelium-derived tumors, such as colorectal adenocarcinoma 
(Marusawa et al., 2011). To address whether endogenous AID expressed in epithelium under 
inflammatory conditions could contribute to carcinogenesis, we made use of the well-
established model of dextran sulfate sodium (DSS)-induced colitis associated cancer (CAC) 
(Cooper et al., 2000). AID-/- mice or AID+/- littermates were treated for 10 cycles with 3% DSS 
and evaluated by pathological criteria. We found that the frequency of oncogenic lesions 
was not significantly different in AID-/- versus AID+/- mice (Figure 23D). These results 
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suggested that endogenous AID does not significantly contribute to colorectal 
adenocarcinoma in the DSS-induced CAC model.  
 
 
Figure 23. Inflammation-induced AID expression does not contribute to carcinogenesis. (A-C). AID 
expression was analyzed in colon and pancreatic human cell lines and in pancreas explants from 
C57BL/6 mice. Samples were treated as indicated with 50ng/ml TNF-a. A) qRT-PCR analysis of AID 
expression in LoVo and SW480 colon cell lines. n(LoVo)= 5; n(SW480)= 3. p(LoVo)=  0.0017; 
p(SW480)=  0.0079. B) qRT-PCR analysis of AID expression in AsPC and PaTU-8988S pancreatic cell 
lines (n=2). p(AsPC)= 0.0369; p(PaTU-8988S)= 0.0119. C) qRT-PCR analysis of AID expression in 
pancreatic explants from wild-type mice (n=3). P= 0.0242. D) AID-/- or AID+/- mice were treated with 
3% DSS for 10 cycles and colonic sections were analyzed by histologic inspection after H/E staining. 
Graphs represent mean frequency values of adenoma and adenocarcinoma lesions of five 
independent experiments. n= (AID-/- Males: 28, Females: 35; AID+/- Males: 23, Females: 25). 
p(Male)= 0.8; p(Female)= 0.246. All data are mean values ± Standard Deviation. Statistical analysis 
was done with two-tailed unpaired Student’s t test.  
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2.2. Generation of conditional AID-expressing mouse models 
The absence of a significant contribution of endogenous AID to carcinogenesis in DSS-
treated mice could be explained by an insufficient amount of AID in this model. Indeed, AID 
expression is known to be limiting for its activity in B cells (Sernandez et al., 2008). To 
directly evaluate whether AID expression can contribute to carcinogenesis, we generated 
two mouse models for conditional AID expression in epithelial cells of colonic and pancreatic 
origin (Figure 24A). We introduced an AID-GFP-encoding cassette in the endogenous Rosa26 
locus preceded by a transcriptional stop flanked by two loxP sites (R26AID+/KI mice). To 
achieve specific expression of AID in epithelial cells, we bred R26AID+/KI mice with mice 
expressing the Cre-recombinase under a villin promoter, which specifically drives expression 
in colon (el Marjou et al., 2004) (R26AID+/KIVillin-CRE+/TG mice), or the pancreas-specific Ptf1 
(p48) gene (Kawaguchi et al., 2002) (R26AID+/KI p48-CRE+/KI mice). R26AID+/+Villin-CRE+/TG and 
R26AID+/+p48-CRE+/KI mice were used as controls. To confirm that the Rosa26 AID-GFP 
cassette was functional, we first evaluated the expression of the reporter protein GFP by 
immunofluorescence in colon of R26AID+/KIVillin-CRE+/TG mice and pancreas of R26AID+/KIp48-
CRE+/KI mice (Figure 24B). GFP was expressed in R26AID+/KIVillin-CRE+/TG colon and 
R26AID+/KIp48-CRE+/KI pancreas but not in control mice (Figure 24B). We next measured AID 
transcript levels by qRT-PCR. In R26AID+/KI Villin-CRE+/TG and R26AID+/KI p48-CRE+/KI mice, the 
amount of AID in the targeted epithelial tissues was similar to that found in B cells activated 
in vitro with LPS+IL4, whereas AID expression in control mice remained at background level 
(Figure 24C). AID is thus expressed in the epithelium of R26AID+/KI Villin-CRE+/TG colon and 
R26AID+/KIp48-CRE+/KI pancreas at levels known to be functional in B cells.  
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Figure 24. Heterologous AID expression in colon and pancreas. A) Schematic of the constructs used 
for conditional expression of AID in epithelial cells. An AID-IRES-GFP cassette preceded by a 
transcriptional STOP flanked by LoxP sites was introduced by homologous recombination within the 
endogenous Rosa26 locus (R26AID+/KI mice, top). R26AID+/KI mice were bred with Villin-CRE and p48-
CRE mice to achieve specific AID expression in colon and pancreas, respectively (bottom). B) GFP 
immunofluorescence in colonic and pancreatic tissue from R26AID+/KIVillinCRE+/TG and 
R26AID+/KIp48CRE+/KI mice. Scale bar: 50 µm. C) qRT-PCR analysis of AID expression in colonic and 
pancreatic tissue from R26AID+/KIVillinCRE+/TG and R26AID+/KIp48CRE+/KI mice. n(R26AID+/+ 
VillinCRE+/TG)= 5; n(R26AID+/KIVillinCRE+/TG)= 4; n(R26AID+/+p48CRE+/KI)= 2, n(R26AID+/KIp48CRE+/KI)= 2. 
LPS+IL4-stimulated B cells are shown as positive control (n=2). Mean values +/- Standard Deviation 
normalized to LPS+IL4-treated B cells are shown.  
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2.3. Conditional AID expression in epithelial cells does not promote adenocarcinoma 
development 
To assess the contribution of AID to adenocarcinoma development, we monitored tumor 
incidence in R26AID+/KI Villin-CRE+/TG and R26AID+/KI p48-CRE+/KI mice. The onset of pancreatic 
and colorectal adenocarcinoma in a variety of mouse models ranges from 5-6 months to 1-
1.5 years (Fodde and Smits, 2001, Aguilar et al., 2004, Martinelli et al., 2016). Therefore, to 
avoid confounding results arising from spontaneous tumorigenesis in very old mice, we set 
analysis end-points at 75-100 weeks. Survival of R26AID+/KIVillin-CRE+/TG mice was 
indistinguishable from that of R26AID+/+ Villin-CRE+/TG littermate controls (Figure 25A, left). 
Likewise, survival of R26AID+/KI p48-CRE+/KI did not differ from that of R26AID+/+ p48-CRE+/KI 
controls (Figure 25A, right). To rule out the presence of early malignancies in aged animals, 
we performed thorough pathological analysis of colon and pancreas sections of all animals, 
but could not detect any tumor development in R26AID+/KI Villin-CRE+/TG and R26AID+/KI p48-
CRE+/KI animals at 75-100 weeks (Figure 25B, C). Expression of AID in colon or pancreatic 
epithelial cells is thus not sufficient to promote tumor development. 
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Figure 25. Heterologous AID expression does not promote carcinoma development. A) Kaplan-
Meier survival curves for R26AID+/KIVillinCRE+/TG (left) (n(R26AID+/+ VillinCRE+/TG)= 47; 
n(R26AID+/KIVillinCRE+/TG)= 38) and R26AID+/KI p48CRE +/KI mice (right) (n(R26AID+/+p48CRE+/KI)= 39; 
n(R26AID+/KIp48CRE+/KI)= 23). B) HE staining in colonic tissue from 75 week-old R26AID+/+VillinCRE+/TG 
(top) and R26AID+/KIVillinCRE+/TG (bottom) mice. Scale bar: 500 µm. C) HE staining in pancreatic tissue 
from 75 week-old R26AID+/+p48CRE+/KI (top) and R26AID+/KIp48CRE+/KI (bottom) mice. Scale bar: 
500 µm. 
2.4. AID generates mutations and DNA double strand breaks in pancreatic 
epithelium  
The failure of AID expression to trigger tumorigenesis prompted us to evaluate its 
activity in epithelial cells. We first analyzed the in vivo mutagenic activity of ectopically 
expressed AID. The primary target sequences for AID mutagenic activity are immunoglobulin 
genes; although other genes are known to be susceptible to AID-induced mutagenesis, this 
occurs at much lower rates (~10-4 mutations/bp) and the mechanisms responsible for this 
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susceptibility are poorly understood. One of the best-characterized requirements for AID 
activity is that the target sequence be transcriptionally active (Chaudhuri et al., 2003, Ramiro 
et al., 2003, Pavri and Nussenzweig, 2011). To simplify the mutagenesis analysis we made 
use of the p48 pancreatic AID expression model to take advantage of the known low 
complexity transcriptome of acinar cells (MacDonald et al., 2010). AID preferentially targets 
the consensus hotspots WRCY/RGYW and particularly AGCT motifs (Rogozin and Kolchanov, 
1992, Pham et al., 2003, Perez-Duran et al., 2012). Based on this, we analyzed the presence 
of mutations in 800-900bp downstream of the transcriptional start site of two highly-
transcribed genes in pancreas, Elastase1 (Ela1) and Elastase2 (Ela2a), by next generation 
sequencing, which allows large number of mutations to be analyzed at a very high depth 
(Perez-Duran et al., 2012). This analysis revealed that mutations are specifically accumulated 
at the Ela1 and Ela2 genes in R26AID+/KIp48-CRE+/KI animals (Figure 26A, B) at frequencies 
similar to those of other non-Ig genes in B cells (Liu et al., 2008). AID activity was verified for 
Ela1 by conventional Sanger sequencing (Table 1). In contrast to previous reports 
(Matsumoto et al., 2007) we did not detect AID-induced mutations at the tumor suppressor 
gene Trp53, where mutation frequency was identical in R26AID+/KIp48-CRE+/KI mice and 
R26AID+/+p48-CRE+/KI controls (Table 1). 
 
Figure 26. AID expression in pancreas promotes DNA lesions. A,B) Analysis of AID mutagenic activity 
in Elastase1 (A) and Elastase2a (B) by next generation sequencing. Pancreatic DNA was isolated from 
pools of R26AID+/KIp48CRE+/KI and control R26AID+/+p48CRE+/KI 20-week old mice, and then PCR-
amplified with specific primers and sequenced as previously described (Perez-Duran et al., 2012). 
Graphs show cytosine mutation frequency overall (total) or at AGCT hotspots. (n=2).p(Elastase1)= 
0.0382; p(Elastase2a)=  0.009. Statistical analysis was done with two-tails unpaired Student’s t test.  
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Table 1. Analysis of AID mutagenic activity by Sanger sequencing.  
To assess whether AID activity in R26AID+/KIp48-CRE+/KI mice leads not only to 
mutations but also to more aggressive lesions, such as DSBs, we quantified γ-H2AX, a histone 
phosphorylation produced in response to this type of DNA damage. For this analysis, we 
generated acinar-cell explants from R26AID+/KIp48-CRE+/KI and control mice, stained them 
with anti-γH2AX, and quantified the intensity of staining per nucleus by high-throughput 
microscopy (HTM). We found that AID expression in R26AID+/KIp48-CRE+/KI mice promoted a 
significant increase in the levels of γ-H2AX (Figure 27A, B), indicating that AID generates 
DSBs in this cellular context.  
 
Figure 27. AID expression in pancreas promotes DNA damage. DNA damage was analyzed in 
pancreas explants from 8-week old mice by staining with anti-γH2AX antibody. A) HTM-mediated 
quantification of γH2AX intensities per nuclei in pancreas explants cultured in vitro for 6 days. Results 
of two independent experiments are shown. P<0.0001. B) Representative images of γH2AX staining 
in pancreas explants from R26AID+/+p48CRE+/KI (top) or R26AID+/KIp48CRE+/KI mice (bottom) (40X 
amplification). Statistical analysis was done with two-tailed unpaired Student’s t test. 
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2.5. AID induces NKG2D ligands, T cell recruitment and apoptotic cell death in 
pancreas 
Activation of the DNA damage response (DDR) pathway induces the expression of 
NKG2D ligands in epithelial cells, which are in turn recognized by NKG2D receptors 
expressed by NK cells and subsets of T cells (Diefenbach et al., 2001, Gasser et al., 2005, 
Raulet et al., 2013, Champsaur and Lanier, 2010). This crosstalk promotes the elimination of 
pre-cancerous cells and is therefore a mechanism to prevent tumor development (Guerra et 
al., 2008). Given that AID expression in pancreas promotes mutations and DNA damage 
without leading to tumor development, we sought for evidence of precancerous cells and 
found that pancreas from aged R26AID+/KIp48-CRE+/KI mice contained more proliferating 
cells, as assessed by Ki67 staining, than control pancreas (Figure 28A), indicating that 
pancreatic AID expression leads to an abnormal rate of cell division. The epithelial identity of 
Ki67+ cells was confirmed both by morphology (Fig. 28A, magnified micrograph on the right) 
and by staining with the epithelium-specific anti-cytokeratin 8 antibody (Figure 28B).  
 
Figure 28. AID expression in pancreas promotes proliferation. Analysis of proliferation was assessed 
in aged mice by Ki-67 immunohistochemistry. A) Representative images of Ki67 staining in pancreas 
from aged (75-week-old) R26AID+/+p48CRE+/KI (top) or R26AID+/KIp48CRE+/KI mice (bottom). Detail is 
shown on the right. Scale bar: 100 µm. Graph shows quantification of Ki67 positive epithelial cells per 
mm2 of tissue (n=8). P= 0.0266. B) Representative immunofluorescence staining of 20-week old 
R26AID+/KIp48CRE+/KI mice: Blue, DAPI; Red, Ki67; Green, CK8. Scale bar: 50 µm. Detail is shown 
(bottom). Bars show mean values +/- Standard Deviation. Statistical analysis was done with two-
tailed unpaired Student’s t test.  
Results 
 
 
89 
 
We next asked whether the NKG2D immune surveillance pathway could be in play in 
R26AID+/KIp48-CRE+/KI mice. To test this hypothesis, we first analyzed the expression of the 
Raeɛ NKG2D ligand in epithelial cells from pancreatic explants of R26AID+/KIp48-CRE+/KI and 
control mice by flow cytometry. Acinar cells from R26AID+/KIp48-CRE+/KI mice expressed 
higher levels of Raeɛ than their control littermates, although the difference was not 
statistically significant (Figure 29A). To assess whether RAE ligands were expressed by 
pancreatic cells in vivo, we prepared pancreas extracts from aged (75-week-old) 
R26AID+/KIp48-CRE+/KI mice and controls, and measured the amount of five RAE isoforms by 
droplet digital PCR (ddPCR). With this technique each sample is fractioned into thousands of 
droplets, in which PCR amplification reactions occur independently, thereby increasing the 
sensitivity and quantitative potential of the amplification. Amplification of RAE isoforms was 
detected in more drops from R26AID+/KIp48-CRE+/KI samples than from controls (Figure 29B), 
indicating that AID promotes the expression of NKG2D ligands in pancreas, most likely as a 
result of DSB and DDR. We found that primary explants from R26AID+/KIp48-CRE+/KI tended to 
be more sensitive to NK-mediated killing than R26AID+/+p48-CRE+/KI littermate controls 
(Figure 29C), indicating that NKG2D ligand expression in AID-expressing pancreas is 
functional. 
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Figure 29. AID expression in pancreas promotes expression of NKG2D ligands. A) Quantitative FACS 
analysis of RAE expression in pancreatic explants from R26AID+/+p48CRE+/KI and R26AID+/KIp48CRE+/KI 
mice. Left: Graph shows mean fluorescence intensity. Each dot represents an individual mouse. 
n(R26AID+/+p48CRE+/KI)= 9; n(R26AID+/KIp48CRE+/KI)= 8. P= 0.077. Right: Representative FACS staining 
for RAE in explants from R26AID+/+p48CRE+/KI (red) and R26AID+/KIp48CRE+/KI mice (black). B) Analysis 
of RAE expression by ddPCR in aged (75-week-old) mice. Data are presented as the percentage of 
positive drops normalized to the mean control value. Each point represents an individual mouse and 
shows the mean amplification from two independent experiments n(R26AID+/+p48CRE+/KI)= 7; 
n(R26AID+/KIp48CRE+/KI)= 9. P= 0.012. C) Analysis of killing activity. Primary explants of pancreatic cells 
from R26AID+/+p48CRE+/KI or R26AID+/KIp48CRE+/KI mice were cultured with primary NK cells and killing 
activity was assessed as described in Methods (n=4). P= 0.19. All data are values +/- Standard 
Deviation. Statistical analysis was done with two-tailed unpaired Student’s t test.  
We next asked if the expression of RAE ligands promoted the recruitment of immune 
cells to R26AID+/KI p48-CRE+/KI pancreas in vivo. Hematoxylin-eosin staining of pancreas 
sections from aged mice clearly revealed the presence of immune infiltrates in AID-
expressing pancreas of R26AID+/KI p48-CRE+/KI mice (Figure 30A). The composition of these 
immune infiltrates was analyzed by antibody staining to detect macrophages (F4/80), B cells 
(Pax5) and T cells (CD3). The vast majority of cells in the immune infiltrates of R26AID+/KI 
p48-CRE+/KI mice were CD3+ T cells (Figure 30B), with only a negligible contribution from B 
cells and macrophages (Figure 30C). 
Results 
 
 
91 
 
 
Figure 30. AID expression in pancreas promotes immune cell recruitment.  A) Hematoxylin-Eosin 
(HE) staining of pancreas from aged (75-week-old) R26AID+/+p48CRE+/KI and R26AID+/KIp48CRE+/KI 
mice. Top: Representative HE staining showing an immune infiltrate in a R26AID+/KIp48CRE+/KI mouse. 
Bottom: Quantification of number of foci per mm2 of tissue. n(R26AID+/+p48CRE+/KI)= 13; 
n(R26AID+/KIp48CRE+/KI)= 21. P= 0.0098. Scale bar: 200 µm. B) CD3 immunohistochemistry of pancreas 
from 75-week-old R26AID+/+p48CRE+/KI and R26AID+/KIp48CRE+/KI mice. Top: Representative image of a 
CD3 infiltrate in a R26AID+/KIp48CRE+/KI mouse. Bottom: Quantification of the number of CD3 positive 
cells per mm2 of tissue. n(R26AID+/+p48CRE+/KI)= 12; n(R26AID+/KIp48CRE+/KI)= 13. P= 0.0149. Scale 
bar: 100 µm. C) Representative image of F4/80 (top) and Pax5 (bottom) staining in a 
R26AID+/KIp48CRE+/KI mouse. All data are values +/- Standard Deviation. Statistical analysis was 
done with two-tailed unpaired Student’s t test. 
To discount age-related effects, we analyzed 20-week-old mice, finding that the 
accumulation of T cell infiltrates is detectable in these young animals (Figure 31). The main 
NKG2D-expressing T-cell subset is the CD8+ population (Raulet et al., 2013), and 
immunofluorescence analysis of immune infiltrates revealed that a high proportion of the 
CD3+ infiltrate is composed of CD8+ T cells (Figure 31), a finding consistent with the reported 
recruitment of CTL cells to pancreatic islets transgenically expressing Raeɛ (Markiewicz et al., 
2012). 
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Figure 31. Immune pancreatic infiltrates are mainly composed by CD8+ T cells. Representative 
immunofluorescence staining of CD3 and CD8 in pancreas from 20-week old R26AID+/+p48CRE+/KI and 
R26AID+/KIp48CRE+/KI mice. Scale bar: 20 µm. 
Finally, we found that aged R26AID+/KIp48-CRE+/KI mice had significantly higher levels 
of pancreatic TNF−α mRNA than control littermates (Figure 32A), indicating that AID 
promotes the expression of effector cytotoxicity. Consistently, R26AID+/KIp48-CRE+/KI 
pancreas contained cells undergoing apoptotic cell death, detected by caspase3 
immunohistochemistry (Figure 32B, p=0.054). Together, these results indicate that 
heterologous AID expression in pancreas promotes a cytotoxic response, most likely arising 
from the generation of genotoxic activity and NKG2D ligand expression and the recruitment 
of NKG2D-expressing CTL cells. 
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Figure 32. AID expression in pancreas promotes a genotoxic response and cell death. A) TNF-
α expression. Total RNA was isolated from pancreas of aged (75-week-old) R26AID+/KIp48CRE+/KI and 
control mice and TNF-α expression was quantified by qRT-PCR. Each dot represents an individual 
mouse. n(R26AID+/+p48CRE+/KI)= 8; n(R26AID+/KIp48CRE+/KI)= 15. P= 0.0392. B) Cell death detection. 
Pancreas from 75-week old R26AID+/+p48CRE+/KI and R26AID+/KIp48CRE+/KI mice were stained with 
anti-caspase-3. Left: Representative staining from an R26AID+/+p48CRE+/KI mouse (top) and an 
R26AID+/KIp48CRE+/KI mouse (bottom). Right: Quantification of number of cells per mm2 of tissue. 
Each dot represents an individual mouse. n(R26AID+/+p48CRE+/KI)= 9; n(R26AID+/KIp48CRE+/KI)= 11. P= 
0.0545. Scale bar: 50 µm. All data are values +/- Standard Deviation. Statistical analysis was 
done with two-tailed unpaired Student’s t test. 
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1. Analysis of the role of CTCF in the GC reaction 
GCs are microstructures where B cells diversify their Ig genes by SHM and CSR and 
their function is absolutely required for a proper immune response. The establishment of 
the GC reaction involves a complex transcriptional program with the coordinated expression 
of gene networks. While the role of master transcriptional regulators of GCs is firmly 
established, the impact of chromatin structure changes during this reaction is poorly 
understood. CTCF is believed to play general transcriptional regulatory roles by establishing 
long-range DNA interactions between distal enhancers and promoters (reviewed in (Ong and 
Corces, 2014). CTCF activity is essential for embryonic development (Fedoriw et al., 2004).), 
and in B cells, it has been found to be critical in V(D)J recombination during B cell 
differentiation in the bone marrow. This defect was associated with a block at the pro-B cell 
stage. Similarly, in T cells, CTCF deficiency impairs growth and cell proliferation causing cell 
differentiation arrest (Heath et al., 2008). However the role of CTCF in mature B cells has not 
previously addressed. We have approached the role of CTCF as a general chromatin 
remodeler during the GC reaction and have shown that CTCF is absolutely required for the 
maintenance of the GC reaction in vivo by modulating the expression of genes required for B 
cell proliferation, including the inhibition of Blimp-1, that programs GC B cells for their entry 
into PC differentiation (Figure 33). Together, we have described the role of CTCF in 
orchestrating transcriptional changes required for GC maintenance and PC differentiation.  
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Figure 33 Model of GC B cell regulation by CTCF.  CTCF acts upstream of Blimp-1 and different genes 
controlling the GC program, preventing the premature transition to PC. In this context, anti-CD40 
stimulation partially rescues CTCF associated phenotype by downregulating Blimp-1. 
1.1. Culture conditions 
Our results show that susceptibility to CTCF deficiency depends on the context on 
which B cells have been activated. In vivo, mature B cell activation in the periphery is 
triggered by the contact with exogenous antigen and T cells that in turn have been 
stimulated by the same antigen. These interactions initiate a cascade that allows B cell 
proliferation and the production of high-affinity and switched antibodies. In vitro, B cell 
activation can be mimicked by the addition of particular cytokines, together with mitogens 
(such as LPS) that induce both CSR and cell proliferation (reviewed in (Stavnezer et al., 
2008)). However, it has long been known that these conditions fail to fully recapitulate in 
vivo GC reaction; for instance, they do not trigger SHM in the variable region of Ig genes 
(Manser, 1987, Di Noia and Neuberger, 2007).  Our comparative transcriptome analysis 
across different B cell stimulation landscapes has revealed that despite sharing a core of a 
few thousands of common genes, a considerable fraction of transcriptional shifts taking 
place in GC B cells are not mirrored by LPS/IL4 stimulation. Interestingly, we show that 
stimulation of B cells in vitro in the presence of T cells activated with CD3 and CD28 is a 
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better surrogate of in vivo stimulation in GCs, as revealed by whole transcriptome analysis. 
We believe that this finding will have an important impact by allowing the study of B cell 
biology in vitro in a more physiological manner. 
1.2. B cells susceptibility to CTCF deficIency 
Our results shown that susceptibility to CTCF deficiency depends on the context on 
which B cell have been activated. In vivo, mature B cell activation in the periphery is 
triggered by the contact with exogenous antigens and antigen-related T cells. These 
interactions initiate a cascade that allows B cell proliferation and the production of high-
affinity and switched antibodies. In vitro, B cell activation can be mimicked by the addition of 
particular cytokines, together with mitogens (such as LPS) that induce both CSR and cell 
proliferation (reviewed in (Stavnezer et al., 2008)). However, despite the efficiency in 
inducing CSR in vitro, current protocols are known to do not completely recapitulate in vivo 
GC reaction, for example, by the absence of SHM in the variable region (Manser, 1987).  We 
have performed a transcriptional analysis comparing the different programs activated in 
each condition. Despite both conditions share a core of common genes, expected 
considering that we compared activated versus resting B cells, LPS/IL4 stimulation does not 
fully recapitulates GC activation at transcriptional level, in key pathways of GC response, 
such as cell cycle. We have improved in vitro B cell stimulation by using T cells to stimulate B 
cells, better mimicking in vivo GC environment at transcriptional level and reflected in CTCF 
deficient associated phenotype. This finding might be relevant to approach B cell biology in 
vitro in a more physiological manner. 
Regardless of the improvement in mimicking in vivo conditions, we were not able to 
fully reproduce in vitro the dramatic effect observed associated to CTCF deficiency in vivo. 
One possible explanation to this difference might lie in the differences of cell proliferation 
rate. GC B cells present one of the fastest rates of cell division, completing a cell cycle 
between 6-12 hours (Hauser et al., 2007, Allen et al., 2007). We have seen that most of the 
phenotype associated to CTCF deficiency might be ascribed to a defective cell cycle. 
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However, in vitro, the proliferation rate observed does not reach the in vivo one. That might 
explain why the effect of CTCF deficiency in vitro is not as prominent as in vivo. Another 
possibility to consider is the kinetics of CTCF depletion. Messenger or protein stability could 
be different in both systems, presumably smaller in vivo, what could explain, together with 
differences in cell proliferation, the magnification of the phenotype associated to CTCF 
deficiency.  
1.3. CTCF control of transcription in GC 
We have found that CTCF controls transcription of more than 2000 genes in 
CD3/CD28 stimulated B cells, mediating both repression and activation. This result 
contrasted with that found in LPS/IL4 stimulated cells where 50 genes were differentially 
expressed. We consider that transcriptional differences observed in our two in vitro systems 
might not be due to differences in CTCF binding between them, given the high conservation 
of CTCF binding among different species (Schmidt et al., 2012) as well as among different cell 
types (Wang et al., 2012, Kunarso et al., 2010, Cuddapah et al., 2009, Heintzman et al., 
2009). Otherwise, we consider that the presence of exogenously added cytokines activates 
survival and proliferation pathways that promote B cell survival independently on CTCF.  
High-throughput studies have revealed that the pattern of CTCF binding in the 
genome is similar to transcription factors such as TAF1 and its binding is enriched in regions 
where gene density is increased, suggesting a role of CTCF in transcription control (Kim et al., 
2007). However, it binds far from promoters, in intergenic regions, making difficult to 
determine the direct role of CTCF in transcription control (Kim et al., 2007). A recent study 
has provided evidences that CTCF generates topological foci that allow regulation of 
constitutive genes. Within these domains, interaction with RNApolII will determine 
transcription of cell-type specific genes (Zhonghui, T. Cell 2015). However, direct role of 
CTCF in global transcription has not been addressed. Here, we have performed an extensive 
analysis of the impact at transcriptional level of CTCF depletion in activated B cells, showing 
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that CTCF controls gene networks involved in key aspects of B cell biology, modulating both 
its activation and its repression.  
Our transciptome results have pointed the relevance of CTCF in controlling key 
pathways of GCs such as B cell receptor signaling and cell cycle. Although we could 
demonstrate the impairment in cell cycle upon CTCF depletion, in this system, addressing 
the role of B cell receptor remains technically difficult. Analysis of BCR signaling requires 
short-time stimulation of B cells with anti-IgM. However, we cannot stimulate in this way our 
naïve CTCFfl/fl-AIDCRETG/+ cells, thus CTCF depletion is only produced after AID expression.  
Considering the relevance of these pathways in B cell activation biology, together 
with the complete absence of CTCF GC deficient cells in vivo, we could consider that in vivo, 
GC is not initiated. However, the conditional model used in this work, as previously 
mentioned, implies GC program activation before CTCF elimination. Thus, we can affirm that 
CTCF is required for the GC program maintenance in this context. The involvement of CTCF 
in GC initiation should be addressed in mature CTCF B cells, obtained, for example, using a 
CRE-recombinase under CD19 promoter. 
 
1.4. CTCF and transition to PC 
The diminished proliferation of CTCF deficient cells together with the upregulation of 
key PC factors, such as Blimp-1 or Syndecan1, suggested that CTCF maintains the GC 
program by repressing the transition to PCs. Upregulation of Blimp-1 upon CTCF depletion 
has been previously found in a lymphoma cell line (Batlle-Lopez et al., 2015).  Our results 
expand this observation to primary B cells. In addition, our transcriptome analysis comparing 
CTCF deficient B cells with PC showed that not only Blimp-1 and Syndecan1, but a number of 
genes were expressed in the same direction. Our results strongly suggest a role of CTCF in 
balancing decision between GC and PC program. 
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Blimp-1 is considered the master regulator of PC differentiation (Shaffer et al., 2002, 
Shapiro-Shelef et al., 2003) by its ability to modulate gene networks involved in cell cycle 
and antibody secretion. In our system, we have seen direct Blimp-1 targets downregulated, 
such as CIITA and Myc that could, at least partially, explain the phenotype associated to 
CTCF deficiency. However, we cannot rule out additional effects directly dependent on CTCF. 
In this regard, in T cells, CTCF depletion has been associated to a strong upregulation of the 
negative regulators of cell cycle p21 (CDKN1A) and p27 (CDKN1B) (Heath et al., 2008), what 
involves CTCF in directly cell cycle control. 
1.5. Rescue of CTCF-deficient associated phenotype by CD40 signaling  
We have found that anti-CD40 treatment of CTCFfl/fl cells partially rescues the 
phenotype associated to CTCF deficiency. CD40 engagement triggers a number of pathways 
in B cells, among cell proliferation, survival and switching can be mentioned (reviewed in 
(Elgueta et al., 2009)). In addition, we and others have shown that signaling through CD40 is 
able to down regulate Blimp-1. This down regulation has been postulated to maintain the GC 
program, avoiding PC differentiation (Randall et al., 1998, Knodel et al., 2001). In our model, 
we observed that CD40 treatment recovered Blimp-1 levels in CTCF deficient cells, increasing 
cell proliferation and survival. These results would be in accordance with previous reports in 
which arrest of cell cycle by Blimp-1 have been shown (Shaffer et al., 2002). Although we 
cannot rule out the possibility that anti-CD40 treatment increases B cell survival and 
proliferation independently on Blimp-1, the effect in survival and proliferation was 
specifically observed in CTCF deficient, but not in control samples.  
 
Together, these results uncover a new role for CTCF in the maintenance of the GC 
program, by promoting cell proliferation and by inhibiting PC differentiation through Blimp-1 
inhibition.  
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2. Contribution of AID to the generation of neoplasias 
2.1. AID expression under inflammatory conditions 
AID expression has been shown to be induced in epithelium under inflammatory 
conditions. In vitro, several studies have demonstrated that AID is induced by TNF-α 
treatment in colon, liver and cholangiocarcinoma-derived cell lines (Marusawa et al., 2011). 
In this regard, our analyses of AID expression in response to TNF-α have confirmed previous 
data in colonic cell lines and have expanded these observations to pancreatic cell lines. In 
addition, we found that primary pancreatic epithelium is also sensitive to TNF-α, suggesting 
that AID expression can indeed take place in non-transformed cells in pro-inflammatory 
contexts. 
However, despite these in vitro evidences of AID induction after inflammatory insults, 
in vivo, only correlative results between the presence of inflammation-associated 
carcinomas and the expression of AID have been provided (Komori et al., 2008, Kou et al., 
2007, Matsumoto et al., 2007). We wanted to further explore the physiological relevance of 
AID expression in promoting epithelium malignant transformation. We found that AID 
deficiency does not reduce the incidence of oncogenic lesions in an inflammation-induced 
carcinoma model in colon. Our results contrast with the finding that AID deficiency reduces 
colon carcinogenesis in a model of chronic inflammation, triggered by IL10 deficiency (Takai 
et al., 2012). It may be that the effect reported by Takai et al. is not specifically driven by 
epithelial cells, but rather by B cells in IL10-/- mice, a possibility that could be tested using 
conditionally rather than constitutively AID-deficient animals.  
2.2. Models of AID expression in epithelium 
Previous reports have claimed that AID heterologous expression leads to epithelial 
cell neoplasia in various tissues (Okazaki et al., 2003, Takai et al., 2009). In those studies 
overexpression was achieved with transgenes, none of which was epithelium specific. In the 
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model generated by Okazaki and colleagues, AID expression was achieved in all the tissues 
by the strong CAG promoter. However, it remains unclear the levels of AID expression 
reached in these tissues, by the lack of a quantitative measure of AID expression. On the 
other hand, Takai and colleagues presented a conditional AID expression transgenic model 
(Muto et al., 2006) in which the expression of AID was achieved by the tissue-nonspecific 
alkaline phosphatase promoter (TNAP), which is a marker of primordial germ cells. In this 
work, although AID expression and protein are shown, the levels obtained in the different 
tissues upon transgene expression are not compared with the physiological levels found in 
an activated B cell. In contrast to these studies, here we have developed epithelium-specific 
conditional knock-in model, directing AID expression to colon and pancreas epithelium, and 
avoiding both widespread expression and transgene-derived artifacts. Remarkably, our 
models allowed B-cell-like AID expression levels, a basic prerequisite for AID to be 
competent, given that its levels are rate limiting in its native context (Sernandez et al., 2008, 
Takizawa et al., 2008).  
Regarding the contribution of AID to carcinoma development, results differ among 
the different models presented. In Okazaki’s work, survival of the five transgenic lines 
generated varied between 40-90 weeks. The authors found a huge proportion of enlarged 
spleen and lymph nodes, with a high prevalence of T cell lymphomas, as well as lung micro-
adenomas. Stickling, the type of tumor and the severity of the phenotype varied among the 
different transgenic lines generated, as well as with ongoing mouse generations. Although 
the authors ascribed this effect to the accumulation of AID-derived mutation in the 
germline, it could be also explained by effects derived from the transgene insertion by itself. 
On the other hand, in the model presented by Takai, survival of AID-Tg mice was similar to 
that found in control mice. In this case, authors found a low prevalence of hepatocellular 
carcinoma (HCC) (27% of mice at 90 weeks), as well as lung and stomach cancer (6.7% of 
mice at 90 weeks). In contrast to these studies, our models of AID expression in pancreas 
and colon did not shown any evidence of carcinoma development. Discrepancy found with 
previous reports might be explained by the used of knock-in models, and by the specific 
expression of AID in epithelial cells. Our results suggest that AID expression is not enough to 
promote tumor development. 
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2.3.  AID activity in epithelial cells 
AID preferentially mutates specific regions of the Ig genes during the processes of 
SHM and CSR. However, in the recent years has become clear the ability of AID of mutating 
non-Ig genes (Liu et al., 2008). Addressing the mutational activity of AID out of Ig genes is 
difficult given the relative low frequency (10-5 to 10-3 mutations per base pair) and the 
widespread nature of AID mutations. Traditionally, AID activity has been measured by 
Sanger-sequencing at specific sites of interest. Here, we have applied a PCR-based NGS 
approach that allows the detection of mutations at frequencies bellow 10-4 per base pair 
(Perez-Duran). Transcription is the main requirement for AID activity. For this reason, we 
focused our mutational analysis on pancreas, given the low complexity transcriptome of 
acinar cells (MacDonald et al., 2010). AID mutagenic activity was detected in two highly 
expressed pancreatic genes (Ela1 and Ela2), which is expected from the well-established link 
between AID activity and transcription of its target genes (Ramiro et al., 2003, Chaudhuri et 
al., 2003, Pavri and Nussenzweig, 2011, MacDonald et al., 2010). Contrary to previous 
reports (Takai et al., 2009, Endo et al., 2008, Matsumoto et al., 2007), we did not find 
evidences of AID-induced mutations at the tumor suppressor Trp53. This discrepancy might 
reflect differences in transcriptional programs activated in different cell types, determining 
AID accessibility to target sequences.   
In our model of AID expression in pancreas, we found that AID expressed ectopically 
in pancreatic cells is able not only to mutate non-immunoglobulin genes but also to generate 
genotoxic DSBs, suggesting that in this context there are no obvious mechanisms for 
negative regulation of AID activity, as they were previously proposed for transgenic AID 
expression in B cells (Muto et al., 2006). Repair of AID-induced mutations promotes 
generation of abasic sites on DNA that result in a single-strand DNA break (SSB). Generation 
of DSBs by AID activity is supposed to occur when two SSBs sites appear in close proximity in 
opposite strands, by the action of different repair pathways that include the action of exo- 
and endonucleases. In switch regions, DSBs are supposed to be favor because of the high 
concentration of AID hotspots in both strands. However, in epithelial cells, generation of 
DSBs by AID activity has not been addressed. In our model, we have detected a significant 
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increase in the proportion of DSBs generated by AID activity in epithelium. In this context, 
DSBs generation cannot be explained by the accumulation of several AID hotspots in a 
particular disposition, as is found in the switch regions, suggesting that the mechanisms 
involved in repairing AID damage in this context might promote the generation of DSBs.  
2.4. Epithelium protection against AID activity 
Data presented in this work indicate that AID activity in pancreas does not promote 
pancreatic carcinogenesis. We propose that an immune surveillance process might be 
activated by AID activity in pancreas, blocking progression of transformed cells. Upregulation 
of NKG2D ligands in cancerous or stressed tissues has been reported to tag cells to be 
eliminated by the immune system (Gasser and Raulet, 2006). Here, we show that AID 
expression triggers the upregulation of Rae in pancreas, in line with the published finding 
that AID promotes an NKG2D immune response in B cells infected with the Abelson murine 
leukemia virus (Gourzi et al., 2006). We have found that NKG2D-expressing pancreatic cells 
mainly recruit CD8+ cells, in accordance with previous reports showing the role of CD8+ T 
lymphocytes in the elimination of transformed cells (Raulet et al., 2013).  Likewise, we have 
found in these tissues an increased cell death, suggesting a genotoxic response promoted by 
the immune infiltration found in epithelium (Model depicted in figure 34). The 
lymphomagenic potential of AID was previously shown to be dampened in B cells (Robbiani 
et al., 2009, Muto et al., 2006), where p53 exerts a cell-intrinsic tumor suppressor function 
(Robbiani et al., 2009). Here we provide evidence of a further protective mechanism 
triggered by AID activity and carried out through an extrinsic immune surveillance pathway 
in epithelial tissues.  
 
Together, data presented in this part of the work uncover a new protective 
mechanism counter-acting AID oncogenic potential through an extrinsic immunosurveillance 
pathway in epithelial cells. These findings challenge the view that AID contribute significantly 
to inflammation-related carcinogenesis.  
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Figure 34. AID-expressing epithelia are protected from neoplastic transformation by an NKG2D 
surveillance pathway. AID expression in pancreas promotes a response that involves NKG2D ligand 
expression, CD8+ T cell recruitment and epithelial cell death.  
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1. CTCF es un remodelador de la cromatina absolutamente necesario para la reacción 
de centro germinal, bien sean constitutivas o de novo. 
2. El contexto en el cual CTCF es eliminador de las células B determina la susceptibilidad 
de dichas células a la falta de este factor. 
3. A nivel transcripcional, la estimulación mediante LPS/IL4 difiere con respecto a la 
reacción de GC in vivo en rutas clave para la biología de estas células. La estimulación 
de células B in vitro a través de la activación de células T, recapitula mejor el 
transcriptoma de los GCs in vivo. 
4. CTCF controla a nivel transcripcional rutas clave de las células B de GC como la 
señalización a través del BCR o el ciclo celular.  
5. La deficiencia de CTCF altera el mantenimiento del programa de GC y provoca la 
transición prematura hacia el programa de PC.  
6. El silenciamiento del regulador maestro de la diferenciación hacia PC Blimp-1, rescata 
de forma parcial el fenotipo asociado a la deficiencia de CTCF  en células B. 
7. La inducción de inflamación promueve la expresión de AID tanto en líneas como en 
células primarias epiteliales. 
8. Los modelos R26AID+/KI Villin-CRE+/TG y R26AID+/KI p48-CRE+/KI permiten la expresión 
específica de AID en colon y páncreas, respectivamente, a niveles similares a los 
obtenidos en células B activadas.  
9. La expresión de AID en colon y páncreas no es suficiente para promover el desarrollo 
tumoral. 
10. La expresión de AID en páncreas promueve una respuesta citotóxica, resultante del 
acúmulo de daño en el DNA, la expresión de ligandos NKG2D y el reclutamiento de 
linfocitos T CD8+. 
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1. CTCF is a chromatin remodeler absolutely required for constitutive and de novo GC 
reactions in vivo. 
2. Stimulation context in which CTCF is depleted in B cells determines the susceptibility 
of these cells to the lack of this factor. 
3. Transcriptionally, LPS/IL4 in vitro stimulation differs to in vivo GC cells in key 
pathways of GC B cell biology. In vitro stimulation of B cells through T cell activation 
better mimics in vivo context. 
4. CTCF controls at transcriptional level key pathways of GC B cells such as B cell 
receptor pathway and cell cycle. 
5. CTCF deficiency impairs the maintenance of the GC program and determines an 
imbalance through the PC program. 
6. Downregulation of the master regulator of PC differentiation Blimp-1 partially 
rescues the phenotype associated to CTCF deficiency in B cells. 
7. Inflammatory stimulation triggers AID expression in epithelial cell lines and in non-
transformed primary pancreatic cells.  
8. R26AID+/KI Villin-CRE+/TG and R26AID+/KI p48-CRE+/KI models allow specific expression 
of AID in colon and pancreas, respectively, at levels similar to those found in 
activated B cells. 
9. AID expression in colon and pancreas is not sufficient to promote tumor 
development. 
10. AID expression in pancreas promotes a cytotoxic response, most likely arising from 
the generation of genotoxic activity and NKG2D ligand expression and the 
recruitment of CD8+ T cells 
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Table1. 20% more significantly downregulated genes in CTCFfl/fl mice compared with control 
mice in CD3/CD28 stimulation.  
 
Gene ave_CTCF fl/fl ave_CTCFfl/+ foldChange adj.P.Val 
Fcer2a 4,41 34,46 -7,70 4,30E-37 
Slc15a3 8,74 46,18 -5,27 1,41E-35 
Zfp280b 74,49 249,15 -3,35 1,78E-33 
Rnf19b 105,12 364,86 -3,47 5,12E-30 
Fmnl2 3,44 23,73 -6,98 1,92E-22 
Rab35 64,56 169,65 -2,63 5,00E-21 
Atp11a 9,97 36,19 -3,63 8,96E-21 
Lifr 11,26 46,30 -4,14 4,00E-20 
Samsn1 48,64 112,00 -2,30 1,70E-17 
Pros1 4,14 20,39 -4,91 4,16E-17 
Insm1 23,55 91,36 -3,86 7,72E-16 
Ctcf 70,69 145,97 -2,06 1,93E-15 
Pkib 67,05 143,96 -2,15 4,36E-15 
Tspan2 39,12 86,63 -2,21 2,89E-14 
Cish 34,22 100,61 -2,94 1,12E-13 
Lta 2,08 12,48 -5,91 2,18E-13 
Parm1 0,46 6,95 -15,02 3,09E-13 
Klhdc2 62,86 134,65 -2,14 3,09E-13 
Lif 2,99 14,78 -4,88 3,59E-13 
Fabp5 20,85 51,35 -2,45 5,16E-13 
Batf3 5,80 25,09 -4,34 6,27E-13 
Il4i1 131,62 274,27 -2,08 1,05E-12 
Sema4b 46,78 109,18 -2,33 1,43E-12 
Cpox 233,90 515,48 -2,20 1,43E-12 
Dock10 171,23 362,34 -2,12 3,77E-12 
Nfil3 68,62 153,03 -2,23 5,10E-12 
Hipk2 106,07 288,25 -2,72 1,03E-11 
Akap2 27,82 59,27 -2,13 1,28E-11 
Mthfd2 62,69 119,41 -1,90 1,87E-11 
Xylt1 2,25 12,46 -5,61 2,04E-11 
Ptgs1 0,34 5,86 -16,59 2,45E-11 
Thy1 14,27 49,35 -3,43 2,80E-11 
Hlx 3,11 14,54 -4,64 4,15E-11 
Pprc1 87,03 166,58 -1,91 5,37E-11 
Marcks 27,39 61,48 -2,23 8,99E-11 
Mat2a 151,33 293,96 -1,94 4,35E-10 
Ifng 6,59 21,25 -3,21 4,84E-10 
Wdr77 45,39 83,32 -1,83 1,09E-09 
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Gm26667 7,20 21,72 -2,97 1,73E-09 
Sypl 50,93 95,61 -1,88 1,79E-09 
Tmed8 92,78 173,71 -1,87 2,27E-09 
Gnl3 64,95 122,33 -1,88 2,60E-09 
Naa25 93,21 172,22 -1,85 2,69E-09 
Pim3 39,97 75,01 -1,88 2,98E-09 
Snhg4 17,91 39,08 -2,17 3,21E-09 
Otulin 104,54 200,20 -1,91 3,51E-09 
Polr1b 66,60 118,04 -1,77 6,82E-09 
Gfi1 90,63 155,53 -1,72 7,78E-09 
Wdr59 26,40 51,02 -1,93 1,42E-08 
Nol9 87,73 151,63 -1,73 1,43E-08 
Gm17300 8,01 22,25 -2,75 1,56E-08 
Gzma 1,55 10,98 -7,04 1,61E-08 
Abcb1b 20,07 41,78 -2,07 2,10E-08 
Ass1 27,33 52,96 -1,94 2,10E-08 
Utp15 56,51 97,33 -1,72 2,16E-08 
Rrp12 58,65 110,12 -1,88 3,58E-08 
Rbpj 69,77 128,20 -1,83 3,64E-08 
Epas1 2,24 9,97 -4,47 3,69E-08 
Rab8b 62,75 104,62 -1,67 3,87E-08 
Egr2 52,54 98,41 -1,88 3,96E-08 
Syngr2 336,51 624,75 -1,86 4,06E-08 
Eef1e1 33,18 59,70 -1,80 4,27E-08 
Ak2 170,51 319,03 -1,87 5,11E-08 
Ptpn3 7,75 20,07 -2,60 6,20E-08 
St7 12,12 27,68 -2,28 6,34E-08 
Ing5 23,78 46,39 -1,95 7,39E-08 
Asns 32,02 60,43 -1,88 1,00E-07 
Cd44 158,75 287,29 -1,81 1,02E-07 
Iigp1 131,55 239,58 -1,82 1,12E-07 
Socs1 104,86 207,08 -1,97 1,18E-07 
Utp20 78,41 134,62 -1,72 1,49E-07 
Ighg1 191,39 343,48 -1,79 1,57E-07 
Mettl16 52,72 88,85 -1,69 1,87E-07 
1110038B12Rik 23,47 46,23 -1,96 1,88E-07 
St6galnac4 80,91 132,28 -1,63 2,08E-07 
Jade2 72,21 123,36 -1,71 2,49E-07 
Rbpsuh-rs3 9,98 22,62 -2,27 3,34E-07 
Il4ra 392,87 692,40 -1,76 3,34E-07 
Serpinb9 36,78 73,55 -2,00 3,89E-07 
Heatr1 130,69 222,92 -1,71 4,80E-07 
Wdr18 53,22 90,11 -1,69 4,88E-07 
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Ccl22 28,91 57,79 -1,99 5,10E-07 
Nabp1 94,36 181,78 -1,93 5,22E-07 
1110032F04Rik 5,29 14,38 -2,69 5,80E-07 
Slc16a1 89,59 144,50 -1,61 7,17E-07 
Slc39a6 29,91 53,51 -1,79 8,07E-07 
Srm 124,28 227,15 -1,83 8,56E-07 
Grwd1 38,16 68,36 -1,79 8,91E-07 
Cirh1a 70,85 113,99 -1,61 9,09E-07 
Ado 35,81 62,80 -1,76 9,58E-07 
Eftud1 34,45 58,74 -1,71 9,80E-07 
Atf3 5,59 14,45 -2,60 1,04E-06 
Nfkb2 167,60 298,03 -1,78 1,15E-06 
Pop1 31,87 57,55 -1,80 1,20E-06 
Dkc1 94,12 155,42 -1,65 1,33E-06 
Dusp10 11,27 25,81 -2,30 1,55E-06 
Wdr75 58,90 95,25 -1,62 1,67E-06 
Pno1 35,54 63,18 -1,78 1,70E-06 
Mfhas1 42,95 73,06 -1,70 1,82E-06 
Spred1 13,59 27,73 -2,04 2,29E-06 
Slpi 3,07 10,03 -3,27 2,31E-06 
Brix1 56,07 89,89 -1,60 2,51E-06 
2410002F23Rik 56,14 92,65 -1,65 2,61E-06 
Amd1 73,88 117,23 -1,59 2,62E-06 
Heatr3 60,80 98,09 -1,61 2,73E-06 
Lad1 1,03 5,62 -5,43 2,82E-06 
Timd2 5,08 13,88 -2,71 2,82E-06 
Zc3h12c 2,25 8,96 -4,03 3,26E-06 
Mdn1 145,61 255,90 -1,76 3,72E-06 
Nol11 49,19 78,81 -1,60 3,72E-06 
Alpl 70,97 112,82 -1,59 3,72E-06 
Tnfrsf8 44,92 99,54 -2,21 3,98E-06 
Ifrd1 23,11 44,63 -1,93 4,79E-06 
Arhgap5 2,77 9,04 -3,24 4,86E-06 
Dusp7 11,02 23,16 -2,10 5,60E-06 
Hspd1 431,84 753,39 -1,74 5,77E-06 
Rcc1 97,49 159,08 -1,63 6,29E-06 
Tbxas1 0,47 4,10 -8,77 6,31E-06 
Mrps18b 35,16 59,37 -1,69 6,83E-06 
Noc4l 99,67 155,93 -1,56 6,83E-06 
Ppargc1b 14,98 30,22 -2,02 7,41E-06 
Utp18 48,21 77,71 -1,61 7,61E-06 
Plagl2 125,44 202,23 -1,61 7,73E-06 
Xpot 101,46 156,30 -1,54 9,68E-06 
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Ncl 1177,19 1930,32 -1,64 9,81E-06 
Ept1 42,20 67,48 -1,60 9,92E-06 
Ndufaf4 15,22 30,43 -2,00 1,12E-05 
Nop2 112,29 188,82 -1,68 1,19E-05 
Naa15 141,34 232,09 -1,64 1,22E-05 
Slco3a1 4,96 13,98 -2,81 1,25E-05 
Sema6d 20,19 39,32 -1,95 1,37E-05 
Urb2 54,88 84,85 -1,55 1,39E-05 
Mybbp1a 430,90 710,20 -1,65 1,48E-05 
Rif1 82,81 126,27 -1,53 1,69E-05 
Chchd4 23,64 42,86 -1,80 1,81E-05 
Yars 101,54 158,17 -1,56 1,81E-05 
2700038G22Rik 11,62 23,77 -2,05 1,83E-05 
Il13 0,08 1,90 -24,37 2,01E-05 
Slc7a5 199,97 350,45 -1,75 2,08E-05 
Htr7 0,13 2,55 -17,26 2,14E-05 
Rrp9 55,81 90,71 -1,62 2,28E-05 
Wdr43 132,11 209,77 -1,59 2,31E-05 
Hist2h2aa1 1,60 9,39 -5,60 2,61E-05 
Slc7a1 136,74 227,51 -1,66 2,64E-05 
Prps1 54,51 83,90 -1,54 2,85E-05 
Grap 81,17 136,06 -1,67 2,88E-05 
Slc25a32 15,73 29,64 -1,88 2,90E-05 
Ipo4 58,08 92,32 -1,59 3,00E-05 
St8sia6 5,21 13,26 -2,57 3,27E-05 
Ccdc86 40,31 64,15 -1,59 3,78E-05 
Mars2 22,84 38,72 -1,70 3,80E-05 
Lipg 1,99 7,07 -3,54 3,83E-05 
Ifrd2 61,36 100,20 -1,63 4,07E-05 
Rrs1 67,88 108,10 -1,59 4,11E-05 
Dnttip2 49,22 76,14 -1,55 4,32E-05 
Abcc1 50,64 76,95 -1,52 4,32E-05 
Bend3 24,17 43,67 -1,80 4,32E-05 
Mrto4 62,52 99,42 -1,59 4,50E-05 
Bysl 43,57 69,95 -1,60 4,55E-05 
Kdm6b 85,39 136,10 -1,60 4,77E-05 
Nol10 40,40 65,65 -1,62 4,79E-05 
Foxn2 31,08 51,69 -1,67 4,87E-05 
Sipa1l3 49,12 80,05 -1,63 5,01E-05 
Akap1 24,02 43,49 -1,81 5,01E-05 
Umps 75,87 115,69 -1,53 5,13E-05 
Dhx33 47,96 75,13 -1,56 5,25E-05 
Ddx21 320,50 516,22 -1,61 5,26E-05 
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Cdk5r1 13,95 27,32 -1,97 5,28E-05 
Cse1l 233,37 370,67 -1,59 5,49E-05 
BC035044 34,92 55,44 -1,59 5,66E-05 
Stau2 7,63 16,14 -2,11 6,03E-05 
Set 518,22 837,02 -1,62 6,15E-05 
Tgif2 16,81 29,82 -1,78 6,20E-05 
Kpna4 92,65 140,53 -1,52 6,21E-05 
Bcat1 52,63 81,11 -1,54 6,30E-05 
Fam136a 33,99 54,85 -1,61 6,44E-05 
Tuba4a 89,52 137,86 -1,54 7,12E-05 
Dnmt3a 103,36 153,67 -1,49 7,93E-05 
Ski 10,42 22,05 -2,12 8,97E-05 
Pag1 32,54 52,14 -1,61 9,15E-05 
Cdk6 27,16 45,04 -1,66 9,62E-05 
Nomo1 109,90 170,98 -1,56 9,76E-05 
Slc16a6 32,76 52,49 -1,60 9,89E-05 
Hist1h2bg 2,24 7,56 -3,40 1,01E-04 
Uchl3 30,09 49,22 -1,63 1,02E-04 
Rrp15 29,32 49,61 -1,69 1,04E-04 
Havcr1 3,41 9,47 -2,79 1,05E-04 
BC037034 13,78 29,57 -2,16 1,10E-04 
Gadd45gip1 40,45 61,37 -1,52 1,11E-04 
Lpp 37,88 72,68 -1,93 1,11E-04 
Pogk 17,72 32,24 -1,82 1,12E-04 
Cflar 123,22 188,83 -1,53 1,14E-04 
Gar1 50,44 77,90 -1,54 1,14E-04 
Ccdc71l 63,11 100,38 -1,59 1,16E-04 
Cluh 139,66 224,58 -1,61 1,18E-04 
Ddx18 77,95 122,31 -1,57 1,21E-04 
D19Bwg1357e 73,59 110,43 -1,50 1,24E-04 
Fastkd5 9,44 18,50 -1,96 1,25E-04 
Gpr33 0,83 4,33 -4,96 1,25E-04 
Nudt4 54,14 84,69 -1,56 1,25E-04 
Tnfaip3 103,57 156,81 -1,52 1,26E-04 
Tsr1 104,75 153,57 -1,47 1,26E-04 
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Table2. 20% more significantly upregulated genes in CTCFfl/fl mice compared with control 
mice in CD3/CD28 stimulation.  
 
Gene ave_CTCF fl/fl ave_CTCFfl/+ foldChange adj.P.Val 
Ccr6 108,75 28,07 3,86 5,15E-41 
Sell 153,09 43,51 3,52 1,77E-38 
Spata13 92,40 25,21 3,67 9,60E-32 
Flt3 15,55 1,33 11,60 1,44E-26 
Pou6f1 159,16 54,77 2,91 2,04E-25 
Txnip 193,52 62,54 3,10 2,04E-24 
Cd24a 622,11 194,05 3,21 2,04E-24 
Cd97 121,49 47,35 2,57 7,00E-22 
Bst1 73,20 24,52 2,98 5,00E-21 
Acss1 88,53 35,25 2,51 1,49E-20 
Stac2 18,84 3,44 5,43 1,58E-18 
Arl5c 95,96 40,50 2,37 3,19E-18 
Cd2 115,12 52,70 2,19 1,03E-17 
Gpr114 22,99 4,67 4,83 1,19E-17 
Aldoc 104,71 19,83 5,30 2,23E-17 
Neurl3 65,99 19,68 3,32 8,53E-17 
Gramd2 45,33 12,50 3,66 2,53E-16 
Ifitm1 12,46 1,24 9,85 7,72E-16 
Itgam 22,38 3,83 5,81 9,74E-16 
Cytip 625,36 240,10 2,60 1,07E-15 
Fcgr2b 219,96 92,64 2,37 2,17E-15 
Trp53inp1 132,51 56,85 2,33 3,29E-15 
Dok3 103,62 43,16 2,40 2,26E-14 
Cyp4f18 25,67 5,59 4,52 2,89E-14 
Fcrla 199,21 83,01 2,40 4,71E-14 
Nod1 33,60 10,44 3,22 4,71E-14 
Arhgef3 78,62 36,54 2,15 5,35E-14 
Rhoh 209,78 95,36 2,20 6,15E-14 
S100a10 58,63 24,49 2,40 7,72E-14 
Susd3 48,87 20,29 2,42 1,14E-13 
Ypel3 69,20 29,14 2,37 1,50E-13 
Nkg7 36,86 10,24 3,55 1,60E-13 
Tg 65,27 27,72 2,37 1,39E-12 
Sfn 58,63 26,28 2,24 1,40E-12 
Slc4a8 21,37 5,12 4,11 2,07E-12 
Nr4a1 107,14 48,95 2,18 2,65E-12 
Bank1 143,22 70,53 2,04 5,39E-12 
Trib2 24,13 7,42 3,26 7,59E-12 
Myl12b 90,23 45,34 1,99 7,75E-12 
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Ret 6,36 0,46 13,15 9,11E-12 
Hes1 20,69 3,83 5,36 9,75E-12 
Bzrap1 57,82 24,72 2,33 1,29E-11 
Tcp11l2 33,89 7,18 4,75 1,43E-11 
Fgd3 75,20 37,68 2,00 1,77E-11 
Pirb 21,01 6,74 3,12 1,04E-10 
Kif19a 12,84 2,94 4,44 1,05E-10 
Sidt1 25,51 8,50 3,03 1,39E-10 
Rhobtb2 184,61 84,36 2,19 2,23E-10 
Prdm1 60,55 18,16 3,36 3,05E-10 
Haao 61,47 30,25 2,03 4,84E-10 
Apold1 9,57 1,31 7,51 5,70E-10 
Blk 159,08 83,13 1,91 7,12E-10 
Sla 138,40 76,63 1,81 7,63E-10 
Pik3ip1 27,88 9,46 2,93 7,66E-10 
Vps37b 231,91 117,01 1,98 7,72E-10 
Rtn4ip1 80,15 38,05 2,10 7,96E-10 
Erdr1 471,48 236,24 2,00 9,20E-10 
Sat1 57,52 28,73 2,00 1,09E-09 
Cxxc5 36,99 15,46 2,39 1,09E-09 
4632428N05Rik 38,03 14,75 2,58 1,09E-09 
Anxa2 40,85 13,83 2,97 1,17E-09 
Abi3 88,23 46,64 1,89 1,25E-09 
Ier5l 44,93 18,89 2,36 1,44E-09 
Tspan13 157,12 74,45 2,11 1,67E-09 
Cd86 190,53 92,12 2,07 1,86E-09 
Unc119b 272,04 145,61 1,87 2,12E-09 
Cerk 249,09 129,91 1,92 2,12E-09 
Padi2 47,47 21,66 2,20 2,52E-09 
Tm6sf1 96,79 54,32 1,78 2,72E-09 
Il1r2 46,81 15,82 2,98 2,98E-09 
Dtx1 144,29 78,99 1,83 3,91E-09 
Syk 1021,60 551,32 1,85 4,54E-09 
Acp5 21,55 8,27 2,61 4,60E-09 
Entpd1 34,09 12,99 2,63 4,60E-09 
Ptpn22 111,70 59,85 1,87 4,71E-09 
Sertad4 10,79 2,35 4,53 4,71E-09 
Tubb2b 26,88 11,11 2,42 5,00E-09 
Anxa6 164,01 84,06 1,95 5,32E-09 
Neil1 77,19 40,70 1,90 5,98E-09 
Gadd45a 25,25 9,97 2,54 6,21E-09 
Sdc1 38,90 18,07 2,16 6,71E-09 
Pde4b 108,47 61,78 1,76 7,72E-09 
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Myo1f 93,64 53,62 1,75 1,35E-08 
Tha1 52,66 22,02 2,39 1,38E-08 
Bmf 12,98 2,69 4,85 1,40E-08 
Stxbp1 78,65 41,37 1,90 1,41E-08 
Stard10 37,39 15,57 2,39 1,51E-08 
Ubac2 129,41 72,18 1,79 1,56E-08 
Tbc1d10c 107,82 63,45 1,70 1,80E-08 
Cpm 20,69 7,61 2,71 1,91E-08 
Map3k9 39,72 19,10 2,08 2,16E-08 
Elmo2 262,95 144,65 1,82 2,17E-08 
Il12a 16,11 5,29 3,04 2,19E-08 
Fcrl1 68,34 36,12 1,88 2,81E-08 
Inpp5k 72,75 40,72 1,78 2,99E-08 
Ccr7 317,90 169,30 1,88 2,99E-08 
Rbl2 105,33 56,94 1,85 3,26E-08 
Il10ra 118,33 67,68 1,75 3,86E-08 
C920025E04Rik 55,92 26,51 2,12 3,86E-08 
Cacna1e 60,16 23,62 2,54 3,96E-08 
Mxd4 41,39 13,86 3,00 4,26E-08 
Ganc 36,60 17,24 2,13 4,28E-08 
Lax1 223,09 120,78 1,85 4,90E-08 
Adamts10 65,55 35,88 1,83 4,97E-08 
Blvrb 41,02 18,99 2,16 5,30E-08 
Mgst2 18,42 5,45 3,37 5,30E-08 
Ackr2 13,37 4,12 3,22 6,15E-08 
Aldh2 321,70 177,41 1,81 6,17E-08 
Scml4 16,54 4,81 3,42 7,23E-08 
Pold4 101,88 54,60 1,87 7,60E-08 
Cd3g 13,53 3,46 3,84 7,89E-08 
Pitpnc1 50,62 23,67 2,14 9,52E-08 
A530040E14Rik 118,44 69,27 1,71 9,74E-08 
Dgka 84,09 48,83 1,73 1,18E-07 
Smim14 94,01 56,25 1,67 1,39E-07 
Cblb 93,48 52,86 1,77 1,51E-07 
Gng2 42,60 19,90 2,13 1,55E-07 
Trim7 16,04 5,55 2,94 1,69E-07 
Bckdha 34,40 16,51 2,09 1,87E-07 
Zfp395 66,93 37,28 1,80 1,91E-07 
Prf1 36,86 15,84 2,31 2,22E-07 
Cd27 29,35 10,77 2,70 2,29E-07 
Ndrg1 52,14 24,02 2,17 2,64E-07 
Arrb1 59,62 24,98 2,39 2,89E-07 
Cd244 6,03 0,74 8,27 3,14E-07 
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Siglecg 194,05 112,22 1,73 3,28E-07 
H2afv 65,86 37,11 1,77 3,58E-07 
Dennd1c 61,49 34,11 1,80 3,58E-07 
Ssbp3 107,67 65,15 1,65 3,80E-07 
Ube2h 149,53 86,94 1,72 4,70E-07 
Sepp1 15,57 5,46 2,82 4,88E-07 
Gm16026 32,78 15,16 2,16 4,90E-07 
Fyn 98,14 57,60 1,70 5,00E-07 
Slc2a3 108,71 47,40 2,30 5,10E-07 
Pld3 58,17 30,85 1,89 5,16E-07 
Itm2a 14,79 5,56 2,66 5,27E-07 
Pbxip1 89,72 52,77 1,71 6,34E-07 
Cables1 42,22 20,06 2,10 9,13E-07 
Abca7 121,62 76,42 1,59 9,16E-07 
Pyhin1 162,83 91,46 1,78 9,32E-07 
B3gnt8 19,67 7,92 2,47 9,44E-07 
Emid1 13,59 4,76 2,83 9,54E-07 
Rab31 26,25 11,20 2,32 9,70E-07 
Acsf2 108,09 65,76 1,64 9,82E-07 
Acot1 5,93 0,94 6,47 1,04E-06 
Ccr5 48,25 20,52 2,35 1,04E-06 
Id3 17,88 6,89 2,58 1,06E-06 
Rnf167 68,36 41,62 1,64 1,15E-06 
Gsn 58,73 28,97 2,03 1,15E-06 
Chst12 57,41 32,95 1,74 1,19E-06 
Trappc6a 66,86 40,23 1,66 1,22E-06 
Aim1 63,00 35,45 1,77 1,41E-06 
Palm 37,41 18,91 1,98 1,50E-06 
Pycard 95,90 59,38 1,62 1,66E-06 
Ildr1 25,26 10,94 2,30 1,66E-06 
Tnfaip8 124,61 77,41 1,61 1,70E-06 
Basp1 27,28 10,99 2,49 1,93E-06 
Cenpa 267,55 157,28 1,70 1,94E-06 
Tmem134 112,74 71,28 1,58 2,01E-06 
Ano10 20,63 9,20 2,24 2,18E-06 
Mta3 110,21 67,16 1,64 2,26E-06 
Fam78a 111,16 68,24 1,63 2,35E-06 
Tecpr1 45,39 24,61 1,84 2,49E-06 
Derl3 27,19 12,65 2,15 2,79E-06 
Pear1 55,76 31,58 1,77 2,82E-06 
Plcg1 64,92 38,31 1,69 3,17E-06 
Rhobtb1 31,11 13,93 2,24 3,21E-06 
Scimp 10,03 3,15 3,14 3,21E-06 
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Lbh 254,37 141,23 1,80 3,59E-06 
Padi3 4,78 0,69 6,57 3,59E-06 
Atp13a2 156,81 100,16 1,57 3,83E-06 
Unc13a 24,38 10,80 2,26 3,85E-06 
Fgl2 156,47 94,67 1,65 4,08E-06 
Ctla4 98,64 53,54 1,84 4,08E-06 
Bcl2l11 502,57 279,61 1,80 4,27E-06 
Slc25a23 19,37 8,07 2,39 4,29E-06 
Hepacam2 14,29 5,13 2,78 4,82E-06 
Tifa 23,64 11,27 2,09 4,89E-06 
Triobp 121,13 72,66 1,67 4,92E-06 
Hexb 47,82 27,56 1,74 4,92E-06 
Csf1 215,14 124,93 1,72 5,71E-06 
C130026I21Rik 97,86 61,23 1,59 5,72E-06 
Hmha1 522,13 314,84 1,66 5,92E-06 
Plgrkt 40,43 22,68 1,78 5,92E-06 
Sipa1l1 139,32 87,67 1,59 5,96E-06 
Klhl6 84,18 52,03 1,62 5,96E-06 
Utrn 72,10 38,91 1,85 6,29E-06 
Pde4a 28,72 13,47 2,13 6,32E-06 
Bfsp2 12,61 4,42 2,86 6,32E-06 
Traf3ip3 130,95 84,86 1,54 6,32E-06 
Mgrn1 119,22 76,62 1,56 6,68E-06 
Srgap3 31,51 13,25 2,38 6,86E-06 
S100a11 55,10 30,33 1,83 7,00E-06 
Gramd1a 156,32 98,01 1,59 7,17E-06 
Gmfg 87,79 55,10 1,60 7,20E-06 
Anxa1 3,32 0,28 10,96 7,51E-06 
Gm2a 191,96 114,93 1,67 7,59E-06 
Ankrd13d 23,42 11,43 2,05 7,59E-06 
Pecam1 72,81 40,95 1,78 7,69E-06 
Grik5 18,59 8,11 2,30 7,74E-06 
Gapdhs 12,47 3,83 3,28 8,14E-06 
Rgs2 12,16 4,28 2,83 8,35E-06 
Ckb 23,55 8,38 2,83 8,90E-06 
Arhgap25 150,87 96,73 1,56 9,33E-06 
Chrna9 4,58 0,71 6,65 9,88E-06 
Gm8369 47,98 25,70 1,87 1,01E-05 
Ccdc102a 12,87 4,98 2,56 1,04E-05 
Ifngr1 42,68 23,50 1,81 1,22E-05 
Il16 153,42 98,99 1,55 1,25E-05 
Hivep2 98,65 61,08 1,61 1,48E-05 
Txndc16 112,29 71,43 1,57 1,51E-05 
Annex 
 
 
143 
 
Serinc5 84,32 53,55 1,57 1,52E-05 
Nxpe3 117,96 73,93 1,59 1,60E-05 
Lag3 150,26 87,14 1,72 1,67E-05 
Bcl7a 146,23 96,34 1,52 1,72E-05 
Carns1 15,82 6,63 2,41 1,73E-05 
Gm9845 6,35 1,39 4,45 1,74E-05 
Ppcdc 47,73 26,45 1,81 1,83E-05 
Dos 20,14 9,67 2,08 1,99E-05 
Fam65c 3,62 0,41 9,20 2,04E-05 
Itga3 7,40 1,91 3,82 2,04E-05 
Emb 26,72 12,35 2,17 2,09E-05 
Nicn1 12,23 4,72 2,57 2,09E-05 
Add1 244,56 155,00 1,58 2,34E-05 
Abcd1 66,36 42,12 1,58 2,47E-05 
Grina 89,70 55,49 1,61 2,50E-05 
Adck3 21,06 9,68 2,16 2,54E-05 
Tmem71 10,96 4,21 2,58 2,55E-05 
Ighg3 165,14 101,76 1,62 2,56E-05 
Coro1b 289,42 180,35 1,60 2,58E-05 
Mical1 131,56 87,26 1,51 2,60E-05 
Igha 32,22 14,73 2,20 2,69E-05 
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Table3. Downregulated genes in CTCFfl/fl mice compared with control mice in LPS/IL4 
stimulation.  
 
Gene ave_CTCF fl/fl ave_CTCFfl/+ foldChange adj.P.Val 
Rsc1a1 0,22 2,85 -13,41 5,18E-05 
Rps13-ps2 0,84 8,93 -10,56 3,52E-03 
Iigp1 1,50 10,62 -7,06 8,24E-07 
Serpina3f 13,49 41,71 -3,09 4,73E-10 
Tgtp1 12,67 32,85 -2,59 5,74E-06 
4930565N06Rik 1,25 3,16 -2,51 2,95E-02 
Rn7sk 24,00 46,04 -1,92 8,09E-06 
BC037034 14,69 27,75 -1,89 1,27E-02 
Gm4759 23,22 42,91 -1,85 7,88E-04 
Rltpr 54,57 99,99 -1,83 1,46E-20 
Ctcf 67,20 120,97 -1,80 8,12E-19 
Ly6c2 3,96 7,12 -1,80 3,04E-02 
Malat1 350,87 550,04 -1,57 2,30E-02 
Gm17132 16,74 25,98 -1,55 2,95E-02 
Serpina3g 98,83 152,53 -1,54 8,09E-06 
Gm15662 205,23 312,38 -1,52 7,88E-04 
Gbp6 63,82 96,21 -1,51 3,71E-03 
Ifi44 11,19 16,81 -1,50 1,88E-02 
Gm17131 55,26 81,59 -1,48 3,52E-03 
Gm26905 127,04 185,58 -1,46 1,27E-02 
Papln 39,46 57,28 -1,45 3,22E-02 
Cacna1e 68,96 100,01 -1,45 4,33E-03 
Gbp2 450,07 652,04 -1,45 2,97E-02 
Tgtp2 46,68 65,70 -1,41 3,22E-02 
Cdh17 38,54 53,64 -1,39 8,11E-03 
Igtp 58,71 81,56 -1,39 3,52E-03 
Cytip 293,99 405,72 -1,38 1,48E-02 
Gbp7 107,09 147,15 -1,37 5,13E-05 
Gm26917 197,33 265,78 -1,35 6,11E-03 
Zbp1 97,46 130,56 -1,34 1,11E-02 
Eng 33,64 44,62 -1,33 1,90E-02 
Spata13 58,82 76,86 -1,31 3,52E-03 
Gbp5 122,27 159,70 -1,31 5,55E-03 
Nlrc5 223,44 288,46 -1,29 3,51E-02 
Cd86 92,77 116,89 -1,26 3,50E-02 
Ubald2 146,06 183,74 -1,26 1,81E-02 
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Table3. Uregulated genes in CTCFfl/fl mice compared with control mice in LPS/IL4 stimulation.  
 
Gene ave_CTCF fl/fl ave_CTCFfl/+ foldChange adj.P.Val 
Spock2 17,67 10,02 1,76 5,74E-06 
Atf5 58,18 39,40 1,48 1,24E-05 
Eps8l1 11,54 0,82 14,01 3,03E-05 
Rpia 91,61 67,13 1,36 4,87E-05 
Hist2h2aa1 2,85 0,55 5,20 5,95E-04 
Fah 47,39 35,33 1,34 3,52E-03 
Chchd10 52,23 40,65 1,29 1,29E-02 
Egr2 43,59 32,49 1,34 1,48E-02 
Vpreb3 40,66 31,87 1,28 2,95E-02 
Srgap3 8,53 5,13 1,66 3,22E-02 
Cpox 130,14 98,51 1,32 5,00E-02 
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